Biotech Industry Financials, Performance and Ratios
-
Industry Score
34.7 /100
Rank 75 out of 131 Industries -
Advance/Decline
252/32
-
No. of Companies284
-
Avg. Market Cap2,732
-
Price to Earning Ratio6.56
-
Price to Earning Growth Ratio0.31
-
Price to Book Ratio14.50
-
Return on Equity14.34
-
Return on Capital Employed-
-
Return on Assets4.77
-
Dividend yield 1 year %0.29 %
-
Net Profit Growth Annual YoY %54.61 %
-
Net Profit Growth Qtr YoY %-8.43 %
-
Net Profit Growth Qtr QoQ %-171.34 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
12,488.9
|
25.1
|
L
H
24.3
25.4
|
L
 10.8%
H
22.4
25.6
|
L
 -0.3%
H
22.4
27.7
|
L
 12.7%
H
22.0
27.7
|
L
 132.0%
H
8.0
27.7
|
L
 170.1%
H
7.9
27.7
|
L
 -19.2%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
1,480.8
|
4.3
|
L
H
4.1
4.3
|
L
 -2.5%
H
4.1
4.6
|
L
 -22.3%
H
4.1
5.9
|
L
 -54.9%
H
4.1
9.8
|
L
 115.2%
H
1.5
9.8
|
L
 159.8%
H
1.0
9.8
|
L
 -70.8%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,811.6
|
22.4
|
L
H
21.7
22.9
|
L
 -1.2%
H
21.7
23.2
|
L
 15.1%
H
18.5
24.9
|
L
 2.1%
H
18.5
24.9
|
L
 146.8%
H
6.5
26.4
|
L
 36.4%
H
6.5
26.4
|
L
 -39.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
169.4
|
3.6
|
L
H
3.6
3.9
|
L
 -8.0%
H
3.6
4.1
|
L
 17.7%
H
2.9
4.5
|
L
 40.2%
H
2.4
4.5
|
L
 77.7%
H
1.4
4.5
|
L
 -52.3%
H
1.2
8.7
|
L
 -85.7%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,070.2
|
3.5
|
L
H
3.4
3.6
|
L
 1.7%
H
3.4
3.7
|
L
 9.6%
H
3.0
3.8
|
L
 -1.9%
H
2.7
4.9
|
L
 47.7%
H
1.9
6.5
|
L
 -52.2%
H
1.9
8.1
|
L
 -88.7%
H
1.9
39.1
|
L
H
1.9
71.9
|
| Arcellx Inc |
|
6,686.0
|
114.3
|
L
H
114.3
114.7
|
L
 0.0%
H
114.3
114.8
|
L
 71.9%
H
63.1
114.8
|
L
 78.8%
H
60.4
114.8
|
L
 60.2%
H
47.9
114.8
|
L
 283.7%
H
27.3
114.8
|
L
H
6.0
114.8
|
L
H
6.0
114.8
|
| Adma Biologics Inc |
|
3,577.2
|
15.0
|
L
H
14.5
15.2
|
L
 0.2%
H
14.5
16.4
|
L
 -8.0%
H
14.5
17.2
|
L
 -23.3%
H
14.5
19.9
|
L
 -27.1%
H
13.8
25.7
|
L
 384.5%
H
2.9
25.7
|
L
 608.5%
H
1.0
25.7
|
L
 159.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,078.8
|
13.5
|
L
H
13.0
13.6
|
L
 8.4%
H
12.7
13.9
|
L
 -15.9%
H
12
17.0
|
L
 -20.6%
H
12
19.8
|
L
 78.6%
H
6.7
20.8
|
L
 68.5%
H
2.3
20.8
|
L
 -67.8%
H
2.3
45.0
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.6
|
1.3
|
L
 -11.4%
H
1.2
1.4
|
L
 -56.8%
H
1.2
2
|
L
 -72.0%
H
1.2
4.5
|
L
 -86.6%
H
1.2
14.7
|
L
 -100.0%
H
1.2
11679.7
|
L
 -100.0%
H
1.2
10000000000
|
L
 -100.0%
H
1.2
10000000000
|
L
H
1.2
10000000000
|
| Agenus Inc |
|
146.3
|
3.8
|
L
H
3.6
3.9
|
L
 27.9%
H
2.9
4.1
|
L
 18.7%
H
2.9
4.1
|
L
 10.8%
H
2.7
4.9
|
L
 120.2%
H
1.4
7.3
|
L
 -88.6%
H
1.4
196
|
L
 -93.7%
H
1.4
196
|
L
 -94.9%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
171.3
|
42.3
|
L
 -1.7%
H
41.7
43.2
|
L
 4.7%
H
39
45.4
|
L
 11.9%
H
37.8
45.8
|
L
 26.7%
H
28
45.8
|
L
 178.7%
H
13.9
45.8
|
L
 443.1%
H
2.7
45.8
|
L
 -78.6%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Avalon GloboCare Corp |
|
3.2
|
0.6
|
L
 1.9%
H
0.5
0.6
|
L
 -22.5%
H
0.5
0.7
|
L
 -6.8%
H
0.4
1.6
|
L
 -54.9%
H
0.4
1.6
|
L
 -91.6%
H
0.4
7.9
|
L
 -77.3%
H
0.2
11.7
|
L
 -95.7%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
110.1
|
1.8
|
L
H
1.4
1.9
|
L
 -60.8%
H
1.1
4.7
|
L
 -64.0%
H
1.1
5.7
|
L
 -63.1%
H
1.1
5.9
|
L
 -72.2%
H
1.1
6.9
|
L
 -75.8%
H
1.1
12.0
|
L
 -84.7%
H
1.1
16.0
|
L
 -59.2%
H
1.1
16.7
|
| Alector Inc |
|
227.3
|
2.1
|
L
H
2.0
2.1
|
L
 -7.6%
H
2.0
2.3
|
L
 2.5%
H
1.9
2.7
|
L
 47.1%
H
1.4
2.7
|
L
 54.9%
H
0.9
3.4
|
L
 -67.4%
H
0.9
9.1
|
L
 -90.2%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
498.9
|
2.2
|
L
H
2.1
2.3
|
L
 -10.1%
H
2.1
2.7
|
L
 4.2%
H
2.0
2.8
|
L
 56.3%
H
1.3
2.8
|
L
 31.4%
H
0.9
2.8
|
L
 -59.6%
H
0.9
6.9
|
L
 -94.0%
H
0.9
38.4
|
L
H
0.9
55
|
| Altimmune Inc |
|
428.3
|
3.4
|
L
H
3.3
3.5
|
L
 -5%
H
3.3
3.7
|
L
 -23.8%
H
3.3
4.8
|
L
 -12.3%
H
3.3
6.4
|
L
 -41.1%
H
2.9
7.7
|
L
 -68.9%
H
2.1
14.8
|
L
 -79.2%
H
2.1
23.5
|
L
 -99.3%
H
1.5
1050
|
| Alvotech |
|
1,115.5
|
3.6
|
L
H
3.4
3.7
|
L
 1.1%
H
3.4
3.9
|
L
 -17.1%
H
3.4
4.3
|
L
 -26.9%
H
3.4
5.6
|
L
 -68.4%
H
3.4
11.9
|
L
 -73.6%
H
3.4
18
|
L
H
3.4
18
|
L
H
3.4
18
|
| Kalaris Therapeutics Inc |
|
127.4
|
6.8
|
L
H
6.7
7.6
|
L
 -25.7%
H
6.7
9.3
|
L
 -38.0%
H
6.7
11.2
|
L
 -25.4%
H
6.7
11.2
|
L
 -40.6%
H
2.1
12.9
|
L
 49.7%
H
0.4
12.9
|
L
 -73.2%
H
0.4
26.5
|
L
H
0.4
49.0
|
| Amgen |
|
188,630.6
|
349.9
|
L
H
347.9
356.3
|
L
 -4.9%
H
347.9
373.0
|
L
 -6.8%
H
347.9
391.3
|
L
 6.9%
H
318.2
391.3
|
L
 10.8%
H
261.4
391.3
|
L
 52.3%
H
211.7
391.3
|
L
 42.3%
H
198.6
391.3
|
L
 140.5%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,860.6
|
64.7
|
L
H
63.1
65.9
|
L
 1.5%
H
63.0
68.4
|
L
 16.7%
H
52.7
68.4
|
L
 31.9%
H
42
68.4
|
L
 293.7%
H
15.4
68.4
|
L
 196.9%
H
12.2
68.4
|
L
 200.7%
H
12.2
68.4
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,677.0
|
74.8
|
L
H
74.0
75.5
|
L
 3.2%
H
70.2
76
|
L
 -4.2%
H
70.2
78.8
|
L
 -9.7%
H
70.2
87.1
|
L
 15.3%
H
56.7
99.5
|
L
 90.1%
H
36.5
99.5
|
L
 117.9%
H
22.3
99.5
|
L
 133.5%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
92.9
|
2.8
|
L
H
2.7
2.8
|
L
 -3.2%
H
2.7
2.9
|
L
 -5.1%
H
2.7
3.1
|
L
 -16.1%
H
2.7
3.6
|
L
 -11.8%
H
2.3
5.5
|
L
 -32.1%
H
2.1
6.5
|
L
 -60.3%
H
2.1
7.1
|
L
 -2.8%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
107.1
|
3.9
|
L
 -15.4%
H
3.8
4.6
|
L
 -28.1%
H
3.8
5.5
|
L
 258.7%
H
1.0
6.9
|
L
 249.1%
H
1
6.9
|
L
 167.8%
H
1
6.9
|
L
 -55.8%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
4.4
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 6.7%
H
0.7
0.8
|
L
 2.6%
H
0.6
0.9
|
L
 -68.1%
H
0.6
2.6
|
L
 -97.3%
H
0.6
35.9
|
L
 -100.0%
H
0.6
27900
|
L
 -100.0%
H
0.6
149400
|
L
 -100.0%
H
0.6
2244000
|
| Aptevo Therapeutics Inc |
|
7.0
|
4.5
|
L
 -3.6%
H
4.4
4.6
|
L
 -1.5%
H
4.3
4.8
|
L
 -35.5%
H
4.0
7.6
|
L
 -76.6%
H
4.0
20.0
|
L
 -99.5%
H
4.0
1299.6
|
L
 -100.0%
H
4.0
1233639.7
|
L
 -100.0%
H
4.0
20184595.2
|
L
H
4.0
68020444.8
|
| AquaBounty Tech Inc |
|
3.6
|
0.9
|
L
H
0.9
1.0
|
L
 -4.2%
H
0.9
1.0
|
L
H
0.9
1.1
|
L
 8.2%
H
0.8
1.2
|
L
 48.4%
H
0.5
3.0
|
L
 -91.7%
H
0.5
12.7
|
L
 -99.4%
H
0.5
162.6
|
L
H
0.5
610
|
| Arvinas Inc |
|
714.4
|
11.2
|
L
H
10.7
11.3
|
L
 -10.5%
H
10.7
12.7
|
L
 -10.2%
H
10.7
14.5
|
L
 -4.4%
H
10.7
14.5
|
L
 28.4%
H
5.9
14.5
|
L
 -62.7%
H
5.9
53.1
|
L
 -83.3%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
7,976.2
|
57.0
|
L
H
55.6
57.4
|
L
 3.5%
H
54.0
58.9
|
L
 -10.8%
H
54.0
67.2
|
L
 -16.4%
H
54.0
76.8
|
L
 268.2%
H
9.6
76.8
|
L
 134.4%
H
9.6
76.8
|
L
 -15.5%
H
9.6
93.7
|
L
 1157.4%
H
1.2
93.7
|
| LeonaBio Inc |
|
92.7
|
9.9
|
L
 1.5%
H
9.0
11.5
|
L
 32.4%
H
6.9
14.2
|
L
 79.6%
H
5.1
14.2
|
L
 42.5%
H
4.2
14.2
|
L
 187.0%
H
2.2
14.2
|
L
 -61.5%
H
2.2
43.0
|
L
 -94.8%
H
2.2
236.4
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
1,870.9
|
14.1
|
L
H
13.9
14.2
|
L
 -2.1%
H
13.9
14.5
|
L
 -2.3%
H
13.5
15.2
|
L
 -13.0%
H
13.5
16.5
|
L
 68.1%
H
6.8
16.5
|
L
 47.9%
H
4.7
16.5
|
L
 3.2%
H
4.1
34.0
|
L
 362.8%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
417.9
|
6.6
|
L
H
6.2
6.7
|
L
 10.6%
H
5.8
7.0
|
L
 22.8%
H
5.1
7.0
|
L
 12.3%
H
4.7
7.0
|
L
 -12.2%
H
4.3
7.7
|
L
 -36.4%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
578.9
|
30.8
|
L
H
30.8
32.5
|
L
 -9.6%
H
30.7
34.7
|
L
 46.8%
H
20.5
36.0
|
L
 57.6%
H
16.8
36.0
|
L
 40.7%
H
13.7
36.0
|
L
 115.9%
H
1.4
61.1
|
L
 -79.5%
H
1.4
158.6
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
694.4
|
14.1
|
L
H
13.1
14.3
|
L
 1.6%
H
13.1
15.2
|
L
 -3.2%
H
13.1
15.3
|
L
 -17.3%
H
12.5
17.5
|
L
 -84.0%
H
6.6
100.1
|
L
 -98.0%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
389.2
|
4.2
|
L
H
4.1
4.3
|
L
 -9.7%
H
4.1
4.9
|
L
 1.9%
H
4.1
5.2
|
L
 14.4%
H
3.5
5.4
|
L
 -57.3%
H
2.9
14.0
|
L
 -55.8%
H
2.9
14.4
|
L
 -71.8%
H
2.9
31.5
|
L
 -14.6%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,127.2
|
158.9
|
L
H
156.4
159.5
|
L
 3.1%
H
153.7
161.4
|
L
 -14.7%
H
153.4
186
|
L
 4.1%
H
148.1
191.5
|
L
 26.2%
H
87.0
191.5
|
L
 153.2%
H
55.0
191.5
|
L
 145.9%
H
19.4
191.5
|
L
 1760.4%
H
1.9
191.5
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -8.7%
H
1.0
1.2
|
L
 -6.3%
H
1.0
1.4
|
L
 78.0%
H
0.5
1.4
|
L
 -39.0%
H
0.5
2.6
|
L
 -73.1%
H
0.5
2.8
|
L
 -93.5%
H
0.5
15.8
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
6.9
|
0.2
|
L
H
0.1
0.2
|
L
 -42.3%
H
0.1
0.3
|
L
 -37.5%
H
0.1
0.3
|
L
 -42.3%
H
0.1
0.3
|
L
 -88%
H
0.1
1.7
|
L
 -97.1%
H
0.1
5.7
|
L
 -99.8%
H
0.1
64
|
L
 -99.9%
H
0.1
444
|
| Autolus Therapeutics PLC (ADR) |
|
380.6
|
1.4
|
L
H
1.4
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -12.8%
H
1.4
1.9
|
L
 -12.3%
H
1.3
2.1
|
L
 -26.3%
H
1.1
2.7
|
L
 -31.6%
H
1.1
7.5
|
L
 -79.3%
H
1.1
8.2
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
13,584.0
|
70.1
|
L
H
68.3
70.7
|
L
 3.1%
H
67.7
72.0
|
L
 -0.9%
H
62.8
75.9
|
L
 -8.2%
H
62.8
84.9
|
L
 107.6%
H
28.3
84.9
|
L
 417.1%
H
11.8
84.9
|
L
 3.6%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
11.9
|
0.2
|
L
H
0.2
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
H
0.2
0.3
|
L
 -78.7%
H
0.1
0.8
|
L
 -55.6%
H
0.1
1.4
|
L
 -93.6%
H
0.1
4.1
|
L
 -99.8%
H
0.1
69.2
|
L
H
0.1
76.6
|
| BioCardia Inc |
|
12.7
|
1.2
|
L
H
1.2
1.3
|
L
 -5.5%
H
1.2
1.4
|
L
 3.5%
H
1.1
1.4
|
L
 -5.5%
H
1.1
1.4
|
L
 -53.5%
H
1
3.2
|
L
 -95.9%
H
1
43.8
|
L
 -98.2%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,460.4
|
9.8
|
L
H
9.1
10.0
|
L
 17.1%
H
8.2
10.0
|
L
 31.2%
H
7.3
10.0
|
L
 32.4%
H
6.2
10.0
|
L
 28.6%
H
6
11.3
|
L
 21.1%
H
4.0
11.3
|
L
 -25.9%
H
4.0
20.0
|
L
 273.0%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
32.8
|
4.5
|
L
H
4.2
4.6
|
L
 5.1%
H
4.1
4.6
|
L
 9.4%
H
3.6
4.6
|
L
 -49.5%
H
3.6
12.1
|
L
 -98.9%
H
3.6
982
|
L
 -100.0%
H
3.6
11514
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
138373.2
|
| Black Diamond Therapeutics Inc |
|
122.5
|
2.2
|
L
H
2.1
2.2
|
L
 0.9%
H
2.1
2.3
|
L
 -6.5%
H
1.9
2.6
|
L
 -15.4%
H
1.9
2.9
|
L
 25%
H
1.2
4.9
|
L
 31.9%
H
1.2
7.7
|
L
 -91.4%
H
1.2
29.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,563.7
|
25.2
|
L
H
24.6
26.0
|
L
 -1.6%
H
24.6
26.3
|
L
 -9.7%
H
24.6
34.2
|
L
 -5.3%
H
24.3
36.4
|
L
 6.5%
H
13.5
36.4
|
L
 -24.2%
H
13.5
49.5
|
L
 -72.9%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
26,917.0
|
183.4
|
L
H
181.7
185.4
|
L
 -0.8%
H
180.5
188
|
L
 -4.5%
H
180.5
198.7
|
L
 4.9%
H
160.4
202.4
|
L
 29.7%
H
110.0
202.4
|
L
 -30.3%
H
110.0
319.8
|
L
 -31.3%
H
110.0
468.6
|
L
 -20.6%
H
110.0
468.6
|
| BioVie Inc |
|
11.0
|
1.5
|
L
H
1.4
1.5
|
L
 5.0%
H
1.3
1.5
|
L
 13.2%
H
1.2
1.5
|
L
 3.6%
H
1.1
1.5
|
L
 -86.2%
H
1.1
13.2
|
L
 -99.9%
H
1.1
1028
|
L
 -99.9%
H
1.1
2386
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,583.6
|
55.0
|
L
H
54.8
55.9
|
L
 -6.8%
H
54.8
60.7
|
L
 -13.2%
H
54.8
66.3
|
L
 -10.0%
H
54.1
66.3
|
L
 -22.8%
H
50.8
73.2
|
L
 -40.0%
H
50.8
100.4
|
L
 -29.6%
H
50.8
117.8
|
L
 -32.0%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
11.4
|
1.1
|
L
H
1.1
1.1
|
L
H
1.1
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 -30%
H
1.1
1.8
|
L
 -66.1%
H
1.1
5.5
|
L
 -90.1%
H
0.1
11.8
|
L
 -98.8%
H
0.1
93.3
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
393.9
|
11.5
|
L
H
11.2
11.9
|
L
 -5.1%
H
11.2
12.5
|
L
 6.1%
H
10.3
13.4
|
L
H
9.9
14.4
|
L
 -26.6%
H
9.9
17.2
|
L
 181.9%
H
1.9
17.2
|
L
 -79.4%
H
1.9
178.3
|
L
 -97.4%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
11.8
|
1.5
|
L
H
1.4
1.5
|
L
H
1.4
1.6
|
L
 -12.7%
H
1.3
1.7
|
L
 -14.7%
H
1.3
1.8
|
L
 -83.4%
H
1.1
8.3
|
L
 -99.6%
H
1.1
415.8
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
35.0
|
1.6
|
L
H
1.6
1.6
|
L
 3.2%
H
1.5
1.8
|
L
 -1.2%
H
1.4
1.8
|
L
 -7.5%
H
1.4
2.1
|
L
 -32.5%
H
1.2
8.1
|
L
 -91.8%
H
0.2
29.6
|
L
 -96.4%
H
0.2
47.1
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
315.6
|
4.6
|
L
 -3.2%
H
4.5
4.7
|
L
 -9.7%
H
4.5
5.3
|
L
 -17.9%
H
4.5
5.9
|
L
 -33.8%
H
4.5
7.3
|
L
 -52.4%
H
4.5
9.9
|
L
 -79.1%
H
4.5
28.9
|
L
 -82.5%
H
4.5
62.1
|
L
H
4.5
62.1
|
| BioNTech SE (ADR) |
|
22,445.9
|
89.3
|
L
H
87.7
89.4
|
L
 -0.9%
H
87.7
95.1
|
L
 -19.1%
H
79.5
112.4
|
L
 -3.5%
H
79.5
124
|
L
 -10.0%
H
79.5
124
|
L
 -31.1%
H
76.5
136.9
|
L
 -17.0%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
292.6
|
3.0
|
L
H
2.9
3.1
|
L
 -4.7%
H
2.8
3.3
|
L
 -3.2%
H
2.8
3.8
|
L
 27.2%
H
2
3.8
|
L
 70.8%
H
1.0
3.8
|
L
 -62.5%
H
1.0
26.4
|
L
 -73.1%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
11.7
|
0.7
|
L
H
0.7
0.8
|
L
 1.4%
H
0.7
0.9
|
L
 42.3%
H
0.5
0.9
|
L
 -88.4%
H
0.5
7.2
|
L
 -63.7%
H
0.5
7.2
|
L
 -88.0%
H
0.5
8.6
|
L
 -99.3%
H
0.5
108.8
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
34.5
|
3.7
|
L
H
3.4
3.7
|
L
H
3.4
4.0
|
L
 2.5%
H
3.4
4.2
|
L
 -7.5%
H
3.4
4.9
|
L
 -76.6%
H
3.4
43.7
|
L
 -98.1%
H
3.4
199.3
|
L
 -99.5%
H
3.4
1067.3
|
L
 -98.0%
H
3.4
1067.3
|
| Crescent Biopharma Inc |
|
-
|
10.6
|
L
H
10.2
10.8
|
L
 -8.1%
H
9.9
12.4
|
L
 -9.5%
H
9.9
13.5
|
L
 -10.4%
H
8.7
14.7
|
L
 -6.4%
H
7.6
21.4
|
L
 262.5%
H
2.8
21.4
|
L
 -23.7%
H
0.9
21.4
|
L
 -82.4%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
254.7
|
2.6
|
L
H
2.5
2.7
|
L
 -5.1%
H
2.5
2.9
|
L
 23.1%
H
2.1
3.8
|
L
 28.6%
H
1.7
3.8
|
L
 22.0%
H
1.1
3.8
|
L
 -33.6%
H
1.1
11.9
|
L
 -93.3%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
199.5
|
2.1
|
L
H
2.1
2.2
|
L
 -4.5%
H
2.1
2.4
|
L
 17.9%
H
1.7
2.4
|
L
 38.8%
H
1.4
2.4
|
L
 33.5%
H
1.1
2.4
|
L
 210.3%
H
0.5
3.0
|
L
 -76.8%
H
0.5
9.4
|
L
 -62.3%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
95.3
|
1.1
|
L
H
1.0
1.1
|
L
H
1.0
1.2
|
L
 -0.9%
H
1
1.2
|
L
 -29.9%
H
1.0
1.6
|
L
 140%
H
0.2
3.8
|
L
 -39.3%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
5.6
|
2.7
|
L
H
2.3
2.7
|
L
 0.8%
H
2.2
3.0
|
L
 12.3%
H
2.2
3.9
|
L
 -66.5%
H
2.2
8.1
|
L
 -81.4%
H
2.2
46.5
|
L
 -96.4%
H
2.2
76.5
|
L
 -99.4%
H
2.2
449.1
|
L
H
2.2
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
65.1
|
11.3
|
L
H
10.9
12.0
|
L
 -6.4%
H
10.9
12.6
|
L
 -2.3%
H
10.9
14
|
L
 -22.9%
H
10.5
16.0
|
L
 19.8%
H
6.3
21.4
|
L
 -57.8%
H
2.3
43.8
|
L
 13.7%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,617.5
|
34.6
|
L
H
33.8
35.2
|
L
 -2.0%
H
33.8
37.2
|
L
 -9.7%
H
33.6
40.5
|
L
 -12.5%
H
32.9
41.4
|
L
 369.0%
H
3.7
43.7
|
L
 202.0%
H
3.7
43.7
|
L
 293.7%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
190.4
|
2.0
|
L
H
1.8
2.0
|
L
 4.2%
H
1.8
2
|
L
 11.9%
H
1.7
2.2
|
L
 17.3%
H
1.4
2.2
|
L
 107.4%
H
0.7
3.5
|
L
 -60.3%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
106.1
|
1.0
|
L
H
0.9
1
|
L
 -9.5%
H
0.9
1.1
|
L
 -6.9%
H
0.9
1.1
|
L
 -5.9%
H
0.9
1.1
|
L
 -19.5%
H
0.8
1.6
|
L
 102.1%
H
0.5
3.1
|
L
 -80%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
10.4
|
0.8
|
L
 -7.3%
H
0.8
0.8
|
L
 -24.8%
H
0.8
1.0
|
L
 -33.3%
H
0.8
1.2
|
L
 -29.0%
H
0.8
1.2
|
L
 -72.7%
H
0.8
3.1
|
L
 -93.0%
H
0.8
20
|
L
 -99.7%
H
0.8
348
|
L
 -99.5%
H
0.8
372
|
| CorMedix Inc |
|
498.0
|
6.3
|
L
H
6.3
6.5
|
L
 -1.6%
H
6.2
6.6
|
L
 -11.0%
H
6.1
7.4
|
L
 -47.6%
H
6.1
13.0
|
L
 -42.6%
H
5.6
17.4
|
L
 82.1%
H
2.6
17.4
|
L
 -36.7%
H
2.6
17.4
|
L
 -50.4%
H
0.9
22.7
|
| CRISPR Therapeutics AG |
|
4,506.5
|
47.0
|
L
H
46.3
48.2
|
L
 -3.9%
H
46.3
50.2
|
L
 -14.1%
H
46.3
61.8
|
L
 -16.0%
H
45.5
61.8
|
L
 12.0%
H
30.0
78.5
|
L
 2.6%
H
30.0
91.1
|
L
 -63.8%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
86.1
|
6.2
|
L
H
5.8
6.2
|
L
 8.0%
H
5.5
6.3
|
L
 2.5%
H
5.5
6.3
|
L
 -14.1%
H
5.5
7.7
|
L
 -38.9%
H
5.5
10.3
|
L
 55%
H
3.6
12.0
|
L
 -50.3%
H
3.6
13.1
|
L
 77.1%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
25.4
|
0.3
|
L
H
0.2
0.3
|
L
 -13.3%
H
0.2
0.3
|
L
 -10.3%
H
0.2
0.4
|
L
 -3.7%
H
0.2
0.5
|
L
 -73.2%
H
0.2
1.1
|
L
 -91.4%
H
0.2
5.1
|
L
 -98.2%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
16.3
|
7.0
|
L
 -3.7%
H
6.8
7.2
|
L
 -2.9%
H
6.8
7.9
|
L
 12.2%
H
6.2
9.0
|
L
 -2.0%
H
4.9
9.0
|
L
 -64.3%
H
4.9
20
|
L
 387.4%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.9
|
1.9
|
L
H
1.8
2.1
|
L
 3.8%
H
1.8
2.2
|
L
 17.7%
H
1.4
2.2
|
L
 2.1%
H
1.4
2.2
|
L
 -64.3%
H
1.4
5.9
|
L
 -67.2%
H
1.4
10.2
|
L
 -99.1%
H
1.4
288
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
650.5
|
5.7
|
L
H
5.6
5.8
|
L
 -13.6%
H
5.6
7.0
|
L
 -30.6%
H
5.6
8.4
|
L
 -10.1%
H
5.6
8.9
|
L
 87.3%
H
2.3
8.9
|
L
 -31.2%
H
2.3
12.8
|
L
 -85.4%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,132.2
|
19.8
|
L
H
18.9
20.2
|
L
 -4.6%
H
18.9
21.4
|
L
 -2.4%
H
18.9
22.6
|
L
 17.2%
H
15.3
23.8
|
L
 33.3%
H
10.6
23.8
|
L
 -15.3%
H
10.6
33.3
|
L
 -68.2%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
47.7
|
2.9
|
L
H
2.8
3.0
|
L
 -4.9%
H
2.8
3.3
|
L
 -17.0%
H
2.8
3.6
|
L
 -35.8%
H
2.8
5.1
|
L
 -36.1%
H
2.8
8.4
|
L
 -16%
H
0.8
13.6
|
L
 -87.5%
H
0.8
24.1
|
L
 -97.7%
H
0.8
308.4
|
| DarioHealth Corp |
|
55.7
|
8.2
|
L
 -7.7%
H
7.6
9.4
|
L
 -9.4%
H
7.6
9.4
|
L
 -27.9%
H
7.6
12.1
|
L
 -28.6%
H
7.6
13.6
|
L
 -42.8%
H
5.9
17.7
|
L
 -89.8%
H
5.9
91.6
|
L
 -97.9%
H
5.9
533
|
L
 -99.5%
H
5.9
2360.0
|
| Bright Minds Biosciences Inc |
|
707.4
|
72.3
|
L
H
69.3
73.1
|
L
 0.0%
H
69.3
76.8
|
L
 -16.0%
H
69.0
91
|
L
 -14.0%
H
69.0
123.8
|
L
 106.5%
H
23.2
123.8
|
L
 2862.3%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
584.4
|
10.3
|
L
 -0.4%
H
10.0
10.5
|
L
 2.4%
H
9.9
11.2
|
L
 -0.2%
H
9.7
11.2
|
L
 6.0%
H
8.2
11.2
|
L
 112.4%
H
2.6
11.2
|
L
 58.3%
H
1.9
11.2
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
166.2
|
6.7
|
L
H
6.5
7.0
|
L
 18.5%
H
5.4
7.6
|
L
 71.4%
H
3.7
7.6
|
L
 49.7%
H
3.5
7.6
|
L
 34.1%
H
3.5
8.8
|
L
 672.4%
H
0.3
19.4
|
L
 -39.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,937.5
|
17.8
|
L
H
17.2
18
|
L
 -1.4%
H
17.2
19.0
|
L
 16.7%
H
14
20.0
|
L
 -10.3%
H
14
21
|
L
 43.6%
H
6.4
25
|
L
 45.2%
H
6.4
47.5
|
L
 12.6%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
230.0
|
2.4
|
L
H
2.3
2.4
|
L
 -7.5%
H
2.2
2.6
|
L
 29.8%
H
1.7
2.8
|
L
 0.4%
H
1.7
2.8
|
L
 69.1%
H
0.9
4.5
|
L
 -71.9%
H
0.9
11.9
|
L
 -94.8%
H
0.9
73.0
|
L
 -92.0%
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
220.4
|
12.0
|
L
H
11.4
12.1
|
L
 9.9%
H
10.7
12.8
|
L
 35.2%
H
8.6
14.9
|
L
 50.9%
H
7.4
14.9
|
L
 52.8%
H
4.6
14.9
|
L
 130.4%
H
3.0
24.4
|
L
 -93.2%
H
3.0
188.8
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,797.0
|
30.1
|
L
H
26.7
31.8
|
L
 4.3%
H
26.7
31.8
|
L
 14.9%
H
25.3
31.8
|
L
 78.1%
H
14.8
31.8
|
L
 43.9%
H
13.3
31.8
|
L
 35.1%
H
9.8
31.8
|
L
 -25.5%
H
3.9
41.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
333.4
|
7.0
|
L
H
6.7
7.2
|
L
 -3.9%
H
6.7
7.5
|
L
 23.8%
H
5.5
8.0
|
L
 63.1%
H
3.5
8.0
|
L
 417.0%
H
1.1
8.0
|
L
 112.8%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
256.4
|
1.1
|
L
H
1.1
1.1
|
L
 0.9%
H
1.0
1.1
|
L
 2.9%
H
1
1.3
|
L
 28.6%
H
0.7
1.3
|
L
 -3.6%
H
0.7
2.1
|
L
 -69.7%
H
0.7
4.6
|
L
 -92.0%
H
0.7
14.0
|
L
 -99.1%
H
0.7
125.2
|
| Enochian Biosciences Inc |
|
-
|
0.4
|
L
 -5%
H
0.4
0.4
|
L
 100%
H
0.2
0.7
|
L
 -34.5%
H
0.2
0.7
|
L
 -63.8%
H
0.2
1.1
|
L
 18.8%
H
0.1
1.7
|
L
 -66.1%
H
0.1
2.3
|
L
 -90.3%
H
0.1
13.8
|
L
 -80.8%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
2.1
|
0.6
|
L
 -7.9%
H
0.5
0.6
|
L
 34.9%
H
0.4
0.7
|
L
 45%
H
0.4
0.8
|
L
 -50%
H
0.3
1.2
|
L
 -84.4%
H
0.3
4.9
|
L
 -92.1%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
130.3
|
2.1
|
L
H
2.1
2.2
|
L
 3.4%
H
2.1
2.7
|
L
 17.6%
H
1.6
2.7
|
L
 86.1%
H
1.1
2.7
|
L
 164.2%
H
0.3
2.7
|
L
 239.7%
H
0.3
3.3
|
L
 -72.6%
H
0.3
8.3
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
3,223.5
|
30.1
|
L
H
29.4
30.3
|
L
 0.4%
H
29.0
31.8
|
L
 1.8%
H
26.8
31.8
|
L
 17.6%
H
19.8
31.8
|
L
 22.2%
H
10.6
31.8
|
L
 297.0%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
33.4
|
4
|
L
 5.8%
H
3.6
4
|
L
 -4.3%
H
3.6
4.6
|
L
 14.9%
H
3.0
4.6
|
L
 -14.9%
H
2.9
5.5
|
L
 115.1%
H
1.2
12.2
|
L
 -61.2%
H
0.8
18.5
|
L
 -94.8%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
125.6
|
1.1
|
L
H
1.0
1.1
|
L
 -7.7%
H
1.0
1.2
|
L
 -22.9%
H
1.0
1.7
|
L
 2.9%
H
1.0
1.7
|
L
 18.7%
H
0.7
1.9
|
L
 -80.5%
H
0.7
8.8
|
L
 -98.8%
H
0.7
97.4
|
L
 -41.0%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
308.3
|
24.6
|
L
H
23.9
25.0
|
L
 -9.3%
H
23.9
29.0
|
L
 -17.1%
H
23.9
33.0
|
L
 -17.1%
H
21.9
35.6
|
L
 250.6%
H
4.9
35.6
|
L
 -1.6%
H
4.1
35.6
|
L
 -96.5%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
458.1
|
9.0
|
L
H
8.6
9.9
|
L
 6.3%
H
8.2
9.9
|
L
 -2.1%
H
8.0
10.5
|
L
 3.5%
H
7.0
10.5
|
L
 136.9%
H
2.2
12.3
|
L
 -47.8%
H
2.2
36.3
|
L
 -79.4%
H
2.2
45.3
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
287.0
|
4.9
|
L
H
4.7
5.0
|
L
 -0.6%
H
4.7
5.2
|
L
 -16.1%
H
4.6
6.0
|
L
 -6.7%
H
4.6
7.0
|
L
 10.1%
H
2.9
7.0
|
L
 -7.9%
H
2.7
10.2
|
L
 -69.7%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
11.1
|
L
 -3.1%
H
10.9
11.4
|
L
 -3.8%
H
10.9
14.8
|
L
 -5.5%
H
10.6
14.8
|
L
 40.4%
H
7.7
14.9
|
L
 -26.8%
H
5.2
55.9
|
L
 -60.1%
H
5.2
55.9
|
L
 -99.4%
H
5.2
1870
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
3.3
|
2.1
|
L
 -2.3%
H
2.1
2.2
|
L
 -5%
H
2.1
2.6
|
L
 -23.2%
H
2.0
2.8
|
L
 -10.3%
H
2.0
5.3
|
L
 397.6%
H
0.4
5.8
|
L
 -96.6%
H
0.4
73
|
L
 -100.0%
H
0.4
62580.4
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
180.5
|
2.8
|
L
H
2.6
2.8
|
L
 -11.4%
H
2.6
3.3
|
L
 -4.4%
H
2.6
3.5
|
L
 -36.1%
H
2.6
4.4
|
L
 78.3%
H
1.1
7.1
|
L
 42.9%
H
0.7
7.1
|
L
 24.4%
H
0.7
7.1
|
L
 107.4%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
73.1
|
1.9
|
L
H
1.9
2.0
|
L
 -30.9%
H
1.9
2.9
|
L
 0.5%
H
1.9
3.1
|
L
 -34.0%
H
1.6
3.5
|
L
 -23.1%
H
1.4
4.3
|
L
 -58.9%
H
0.9
6.2
|
L
 -84.4%
H
0.9
17.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
12.3
|
1.1
|
L
H
1
1.1
|
L
 -1.9%
H
1
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 -25.5%
H
0.7
1.6
|
L
 -60.1%
H
0.7
3.7
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
992.8
|
1.6
|
L
H
1.4
1.6
|
L
 -3.1%
H
1.4
1.7
|
L
 -19.3%
H
1.4
2.0
|
L
 16.5%
H
1.3
2.0
|
L
 -8.8%
H
1.0
2.0
|
L
 -38.7%
H
1.0
5.3
|
L
 -15.3%
H
1.0
5.3
|
L
 -45.8%
H
0.8
7.0
|
| Gilead Sciences |
|
175,176.9
|
141.1
|
L
H
140.1
142.1
|
L
 -2.3%
H
139.2
148.2
|
L
 -6.6%
H
139.2
153.3
|
L
 13.5%
H
116.9
157.3
|
L
 31.3%
H
93.4
157.3
|
L
 82.5%
H
62.1
157.3
|
L
 118.9%
H
57.2
157.3
|
L
 56.3%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
358.6
|
25.9
|
L
H
24.6
26.5
|
L
 -2.5%
H
24.6
30.3
|
L
 3.8%
H
21.6
30.3
|
L
 98.9%
H
13.1
34.1
|
L
 126.0%
H
7.8
34.1
|
L
 99.5%
H
7.6
34.1
|
L
 -13.7%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,224.5
|
16.1
|
L
H
15.4
16.3
|
L
 0.1%
H
15.4
16.9
|
L
 -16.2%
H
15.4
20.4
|
L
 3.4%
H
13.7
25.8
|
L
 139.7%
H
3.5
25.8
|
L
 122.4%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
3.2
|
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 -23.1%
H
1.4
1.9
|
L
 -8.3%
H
1.4
2.0
|
L
 -64.1%
H
1.3
5.6
|
L
 -95.9%
H
1.3
35.2
|
L
 -99.4%
H
1.3
296.3
|
L
 -99.9%
H
1.3
2812.5
|
L
 -100.0%
H
1.3
379518072.3
|
| Graphite Bio Inc |
|
669.1
|
11.5
|
L
 -2.0%
H
11.2
11.9
|
L
 -2.8%
H
11.2
12.7
|
L
 -4.7%
H
11.2
15.0
|
L
 -36.2%
H
11.2
21.8
|
L
 -57.1%
H
11.2
50.4
|
L
 -90.5%
H
11.2
413
|
L
H
11.2
1666
|
L
H
11.2
1666
|
| Galapagos NV (ADR) |
|
2,143.6
|
32.5
|
L
H
32.2
32.8
|
L
 1.9%
H
31.6
33.4
|
L
 -4.8%
H
31.6
36.2
|
L
 0.5%
H
31.6
36.2
|
L
 24.6%
H
22.6
37.8
|
L
 -16.5%
H
22.4
45.2
|
L
 -60.4%
H
22.4
83.8
|
L
 -22.4%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
7,466.9
|
63.3
|
L
H
62.6
64.4
|
L
 -0.5%
H
62.6
65.8
|
L
 -12.2%
H
62.6
72.7
|
L
 -6.1%
H
62.6
82.2
|
L
 -1.6%
H
47.5
82.2
|
L
 91.3%
H
29.9
82.2
|
L
 43.4%
H
29.9
82.2
|
L
 654.1%
H
7.7
82.2
|
| HCW Biologics Inc |
|
4.3
|
0.8
|
L
H
0.7
0.9
|
L
 33.9%
H
0.5
1.2
|
L
 25%
H
0.5
1.2
|
L
 -52.2%
H
0.5
1.7
|
L
 -94.0%
H
0.2
17.8
|
L
 -98.5%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
39.7
|
3.4
|
L
 -3.4%
H
3.2
3.5
|
L
 -19.5%
H
3.2
4.4
|
L
 -25.1%
H
3.2
5.3
|
L
 45.7%
H
2.4
5.8
|
L
 154.1%
H
1.1
9.1
|
L
 -84.4%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
154.6
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -11.8%
H
0.8
1.0
|
L
 -31.1%
H
0.8
1.3
|
L
 -36.9%
H
0.8
1.6
|
L
 -66.5%
H
0.8
2.6
|
L
 -64.7%
H
0.5
3.9
|
L
 -94.8%
H
0.5
19.0
|
L
 -95.2%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
9.1
|
2.4
|
L
H
2.3
2.4
|
L
 -7.8%
H
2.3
2.6
|
L
 -36.6%
H
2.1
4
|
L
 -73.5%
H
2.1
11.5
|
L
 -64.6%
H
2.1
38.3
|
L
 -97.5%
H
2.1
136.5
|
L
 -98.4%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
164.0
|
0.9
|
L
H
0.8
1.0
|
L
 -25.4%
H
0.8
1.2
|
L
 -26.1%
H
0.8
1.3
|
L
 -23.4%
H
0.8
1.3
|
L
 -74.3%
H
0.8
3.4
|
L
 -71.1%
H
0.8
10.0
|
L
 -92.1%
H
0.8
17.5
|
L
H
0.8
17.5
|
| Immucell Corp |
|
55.6
|
6.2
|
L
H
6.0
6.2
|
L
 -7.2%
H
6
6.7
|
L
 -7.8%
H
6
6.7
|
L
 3.0%
H
5.8
7.1
|
L
 27.6%
H
4.5
7.6
|
L
 26.3%
H
3.3
7.6
|
L
 -44.9%
H
3.3
11.5
|
L
 -11.0%
H
3.3
13.2
|
| InflaRx N.V. |
|
61.6
|
0.9
|
L
 3.4%
H
0.8
0.9
|
L
 -7.1%
H
0.8
1.0
|
L
 4.6%
H
0.8
1.0
|
L
 -18.0%
H
0.8
1.2
|
L
 -28.9%
H
0.7
1.9
|
L
 -45.2%
H
0.7
7.3
|
L
 -80.2%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
63.6
|
5.7
|
L
H
5.4
6.0
|
L
 -5.2%
H
5.4
6.5
|
L
 -15.1%
H
5.4
7.3
|
L
 -7.9%
H
5.4
7.6
|
L
 -63.5%
H
5.4
18
|
L
 -88.5%
H
5.4
91.7
|
L
H
5.4
451.3
|
L
H
5.4
451.3
|
| Illumina Inc |
|
19,355.6
|
126.6
|
L
H
121.5
127.4
|
L
 9.5%
H
116.1
127.4
|
L
 5.5%
H
115.3
134.8
|
L
 -6.1%
H
112.7
155.5
|
L
 49%
H
68.7
155.5
|
L
 -43.6%
H
68.7
233.4
|
L
 -69.6%
H
68.7
526
|
L
 -15.7%
H
68.7
555.8
|
| Immunome Inc |
|
2,356.6
|
20.8
|
L
H
20.0
21.0
|
L
 -0.8%
H
19.8
21.4
|
L
 -5.9%
H
19.8
22.9
|
L
 -2.9%
H
19.2
27.7
|
L
 143.1%
H
5.2
27.7
|
L
 266.1%
H
4.4
31.0
|
L
 -42.2%
H
2.1
41.7
|
L
H
2.1
63.8
|
| Imunon Inc |
|
10.0
|
3.0
|
L
H
2.9
3
|
L
 -6.1%
H
2.9
3.2
|
L
 -9.5%
H
2.9
3.6
|
L
 -21.3%
H
2.9
4.2
|
L
 -78.8%
H
2.9
47.4
|
L
 -85.1%
H
2.9
54.8
|
L
 -99.4%
H
2.9
486
|
L
 -99.9%
H
2.9
5607
|
| Immatics N.V |
|
1,302.1
|
9.7
|
L
H
9.4
9.8
|
L
 3.2%
H
9.1
10.3
|
L
 -5.7%
H
9.1
10.6
|
L
 -5.5%
H
8.6
10.9
|
L
 80.8%
H
3.3
12.4
|
L
 27.8%
H
3.3
13.8
|
L
 -31.6%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
4,813.5
|
23.7
|
L
H
23
23.9
|
L
 -5.4%
H
23
25.8
|
L
 -10.3%
H
23
29.3
|
L
 -11.4%
H
23
29.3
|
L
 25.3%
H
12.7
29.3
|
L
 52.6%
H
12.7
45.6
|
L
 39.1%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
16.8
|
1.7
|
L
 -6.5%
H
1.7
1.8
|
L
 -10.0%
H
1.7
2.1
|
L
 7.5%
H
1.5
2.1
|
L
 42.2%
H
1.2
2.7
|
L
 616.7%
H
0.1
4.2
|
L
 47.0%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,073.4
|
64.9
|
L
 -5.6%
H
62.7
68.2
|
L
 -6.4%
H
62.7
72.7
|
L
 -20.0%
H
62.7
82.6
|
L
 -24.7%
H
62.7
94.6
|
L
 363.4%
H
10.8
94.6
|
L
 210.4%
H
10.8
94.6
|
L
 192.7%
H
7.7
94.6
|
L
H
7.7
94.6
|
| MiNK Therapeutics Inc |
|
45.7
|
9.7
|
L
 3.0%
H
8.9
9.7
|
L
 -5.3%
H
8.9
10.2
|
L
 -13.0%
H
8.9
16.9
|
L
 -16.0%
H
8.9
16.9
|
L
 23.0%
H
6.3
76
|
L
 -56.1%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
32.4
|
1.2
|
L
H
1.2
1.3
|
L
 -8.3%
H
1.2
1.4
|
L
 -7.6%
H
1.2
1.5
|
L
 -33.3%
H
1.2
1.9
|
L
 -85.3%
H
1.2
11.6
|
L
 -81.5%
H
1.2
14.7
|
L
 -91.2%
H
1.2
30.4
|
L
H
1.2
30.4
|
| IO Biotech Inc |
|
13.7
|
0.2
|
L
H
0.2
0.2
|
L
 -13.6%
H
0.1
0.2
|
L
 -47.2%
H
0.1
0.4
|
L
 -71.2%
H
0.1
0.8
|
L
 -78.9%
H
0.1
2.8
|
L
 -90.4%
H
0.1
2.8
|
L
H
0.1
17.9
|
L
H
0.1
17.9
|
| Iovance Biotherapeutics Inc |
|
1,594.3
|
3.9
|
L
H
3.6
3.9
|
L
 -4.9%
H
3.6
4.2
|
L
 35.8%
H
2.8
5.6
|
L
 56.1%
H
2.2
5.6
|
L
 8.7%
H
1.6
5.6
|
L
 -40.1%
H
1.6
18.3
|
L
 -87.7%
H
1.6
34.0
|
L
 -22.6%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
447.5
|
2.5
|
L
H
2.3
2.5
|
L
 -0.4%
H
2.2
2.6
|
L
 16.4%
H
2.0
3.0
|
L
 176.7%
H
0.8
3.0
|
L
 329.3%
H
0.3
3.0
|
L
 -35.5%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,257.9
|
59.2
|
L
H
57.7
60.4
|
L
 -1.0%
H
57.7
62.5
|
L
 -6.6%
H
57.7
69.4
|
L
 -26.1%
H
40
83.9
|
L
 10.1%
H
30.8
99.5
|
L
 171.9%
H
18.3
99.5
|
L
 -65.6%
H
11.6
178.3
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
409.8
|
1.5
|
L
H
1.4
1.5
|
L
 -19.4%
H
1.4
1.9
|
L
 -9.9%
H
1.4
2.0
|
L
 -37.0%
H
1.4
3.0
|
L
 101.4%
H
0.5
3.1
|
L
 -4.0%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,522.9
|
30.0
|
L
H
29.7
30.8
|
L
 -3.2%
H
29.7
31.4
|
L
 -9.4%
H
29.7
34.9
|
L
 -16.6%
H
29.7
37.3
|
L
 4.6%
H
23.2
40.7
|
L
 -41.1%
H
23.2
77.0
|
L
 -30.8%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
60.4
|
0.4
|
L
H
0.4
0.4
|
L
 -85.1%
H
0.4
0.6
|
L
 -85.7%
H
0.4
3.0
|
L
 -84.4%
H
0.4
3.3
|
L
 -78.5%
H
0.4
3.5
|
L
 -77.1%
H
0.4
3.9
|
L
 -86.2%
H
0.4
5.4
|
L
 -86.7%
H
0.4
8.0
|
| Inventiva (ADR) |
|
1,254.2
|
6.0
|
L
H
5.8
6.1
|
L
 -2.1%
H
5.8
6.3
|
L
 -9.9%
H
5.8
7.1
|
L
 43.5%
H
4.2
7.3
|
L
 109.7%
H
2.7
8.0
|
L
 32.5%
H
1.5
8.0
|
L
 -51.9%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
861.4
|
14.2
|
L
H
13.6
14.3
|
L
 1.6%
H
13.4
14.4
|
L
 5.5%
H
13.0
14.5
|
L
 2.7%
H
12.1
15.5
|
L
 -54.2%
H
12.1
35.3
|
L
 18.7%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
34.1
|
1.2
|
L
H
1.2
1.3
|
L
 -3.9%
H
1.2
1.3
|
L
 -12.9%
H
1.2
1.5
|
L
 -34.4%
H
1.1
2.1
|
L
 -76.5%
H
1.1
7.2
|
L
 -34.8%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
497.3
|
8.6
|
L
 0.4%
H
8.5
8.6
|
L
 -0.8%
H
8.5
9.1
|
L
 -0.5%
H
8.4
9.4
|
L
 18.4%
H
6.9
9.4
|
L
 29.0%
H
5.5
9.4
|
L
 103.8%
H
4.1
9.4
|
L
 34.9%
H
3.7
9.4
|
L
 123.3%
H
3.5
13.3
|
| Kodiak Sciences Inc |
|
1,383.4
|
22.7
|
L
H
21.3
22.8
|
L
 -4.8%
H
21.3
24.5
|
L
 -15%
H
21.3
28.9
|
L
 -12.9%
H
20.9
31.2
|
L
 576.4%
H
1.9
31.2
|
L
 342.6%
H
1.4
31.2
|
L
 -82.6%
H
1.4
133.7
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
7,541.9
|
258
|
L
H
249.1
258.3
|
L
 2.7%
H
246
259.3
|
L
 -1.8%
H
244.5
277.0
|
L
 7.1%
H
235.6
298.3
|
L
 36.4%
H
122.8
298.3
|
L
 247.0%
H
72.2
298.3
|
L
 237.0%
H
38.9
298.3
|
L
H
8.0
298.3
|
| TuHURA Biosciences Inc |
|
101.1
|
1.8
|
L
H
1.8
1.9
|
L
 -8.7%
H
1.8
2.3
|
L
 61.3%
H
1.0
2.3
|
L
 118.3%
H
0.4
2.3
|
L
 -53.5%
H
0.4
4.4
|
L
 -98.7%
H
0.2
209.3
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
744.6
|
8.4
|
L
H
8.2
8.5
|
L
 -4.6%
H
8.2
9
|
L
 -1.8%
H
7.8
9.6
|
L
 -14.3%
H
7.4
11.3
|
L
 16.0%
H
5.4
12.5
|
L
 -28.1%
H
5.4
24.2
|
L
 -68.7%
H
5.4
30.4
|
L
 94.2%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,496.3
|
79.6
|
L
H
76.9
80.7
|
L
 2.7%
H
76.9
82.5
|
L
 -8.0%
H
76.9
95.9
|
L
 -5.3%
H
66.2
95.9
|
L
 134.9%
H
19.4
103
|
L
 156.3%
H
9.6
103
|
L
 78.2%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
49.1
|
6.7
|
L
H
6.6
6.8
|
L
 -6.7%
H
6.6
7.3
|
L
H
6.6
7.5
|
L
 5.7%
H
6.0
7.5
|
L
 14.9%
H
3.5
7.5
|
L
 -82.2%
H
0.7
38.1
|
L
 -89.5%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
32.5
|
1.1
|
L
H
0.9
1.1
|
L
 37.0%
H
0.8
1.2
|
L
 98.2%
H
0.5
1.2
|
L
 98.2%
H
0.5
1.2
|
L
 -35.1%
H
0.5
1.9
|
L
 -96.0%
H
0.5
44
|
L
 -98.5%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
25.3
|
2.9
|
L
 3.2%
H
2.8
3.1
|
L
 -10.2%
H
2.8
3.3
|
L
 -7.6%
H
2.4
3.3
|
L
 -32.6%
H
2.4
4.3
|
L
 138.5%
H
0.6
6.3
|
L
 -54.6%
H
0.6
9.6
|
L
 -92.3%
H
0.6
49.5
|
L
 -78.0%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
40.2
|
0.7
|
L
H
0.7
0.7
|
L
 18.3%
H
0.6
0.8
|
L
 6.0%
H
0.5
0.8
|
L
 -45.4%
H
0.5
1.3
|
L
 69.1%
H
0.2
3.7
|
L
 -80.5%
H
0.2
10.2
|
L
 -97.1%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
463.0
|
4.5
|
L
H
4.2
4.7
|
L
 -6.3%
H
4.2
5.0
|
L
 43.7%
H
2.7
6.4
|
L
 22.5%
H
2.7
6.4
|
L
 73.9%
H
1.6
6.4
|
L
 -16.9%
H
1.6
13.7
|
L
 -75.5%
H
1.5
18.4
|
L
 -93.9%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
484.1
|
20.8
|
L
 3.5%
H
19.8
21.1
|
L
 -16.2%
H
18.9
25.5
|
L
 -3.8%
H
18.9
27.8
|
L
 -37.7%
H
18.9
45
|
L
 78.4%
H
7.7
45
|
L
 -51.2%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
175.3
|
2.6
|
L
H
2.5
2.7
|
L
 -4.4%
H
2.5
2.8
|
L
 21.4%
H
2.0
2.9
|
L
 25.5%
H
1.6
2.9
|
L
 56.3%
H
1.4
4.7
|
L
 6.1%
H
0.8
4.7
|
L
 -70.3%
H
0.8
9.6
|
L
 -99.4%
H
0.8
598.4
|
| Seres Therapeutics Inc |
|
82.1
|
9.1
|
L
H
8.7
9.2
|
L
 0.3%
H
8.6
9.5
|
L
 3.9%
H
8.1
9.6
|
L
 -39.4%
H
7.9
16.4
|
L
 1064.1%
H
0.4
30.0
|
L
 61.9%
H
0.4
30.0
|
L
 -57.7%
H
0.4
30.0
|
L
 -63.3%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
591.6
|
7.4
|
L
H
7.2
7.5
|
L
 -3.8%
H
7.2
7.9
|
L
 -2.5%
H
6.6
8.0
|
L
 -8.5%
H
6.6
8.5
|
L
 -5.4%
H
4.6
9.7
|
L
 35.9%
H
3.5
9.7
|
L
 -54.1%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
1,918.3
|
23.3
|
L
 -2.6%
H
23.1
24.1
|
L
 -13.8%
H
23.1
28.7
|
L
 -17.0%
H
23.1
31
|
L
 -36.8%
H
23.1
38.2
|
L
 39.0%
H
10.4
47.7
|
L
 50.8%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
392.1
|
58.7
|
L
H
54.2
60.6
|
L
 1.9%
H
54.2
64.9
|
L
 7.3%
H
50.7
64.9
|
L
 -14.5%
H
50.7
76.1
|
L
 50.1%
H
26.1
105
|
L
 319.1%
H
1.4
105
|
L
 66.4%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
22.0
|
1.3
|
L
H
1.3
1.4
|
L
 -2.2%
H
1.3
1.5
|
L
 -12%
H
1.3
1.7
|
L
 3.1%
H
1.3
2.5
|
L
 1.5%
H
0.8
4.1
|
L
 -27.9%
H
0.7
9.7
|
L
 -94.5%
H
0.7
36.5
|
L
 -98.3%
H
0.7
135.5
|
| Moderna |
|
20,683.0
|
52.4
|
L
H
51.0
52.9
|
L
 -1.9%
H
51.0
56.5
|
L
 5.4%
H
48.1
59.6
|
L
 54.9%
H
29.1
59.6
|
L
 57.2%
H
22.3
59.6
|
L
 -65.1%
H
22.3
170.5
|
L
 -63.6%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
443.5
|
3.0
|
L
H
3
3.1
|
L
 -7.9%
H
3.0
3.4
|
L
 -1.6%
H
3.0
3.9
|
L
 -11.7%
H
2.9
4.1
|
L
 24.7%
H
1.7
4.1
|
L
 -78.7%
H
1.7
16.6
|
L
 -91.4%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
80.0
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 -10.7%
H
0.7
0.9
|
L
 2.7%
H
0.7
0.9
|
L
 -50%
H
0.6
1.7
|
L
 -77.1%
H
0.6
3.2
|
L
 -83.2%
H
0.6
5.5
|
L
 -87.2%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
7.4
|
0.6
|
L
H
0.6
0.6
|
L
 -22.4%
H
0.6
0.8
|
L
 -6.4%
H
0.6
0.9
|
L
 -50.8%
H
0.6
1.6
|
L
 -86.2%
H
0.6
5.3
|
L
 -99.8%
H
0.6
268
|
L
H
0.6
1200
|
L
H
0.6
1200
|
| Mesoblast Ltd (ADR) |
|
1,904.4
|
14.8
|
L
H
14.3
14.8
|
L
 -1.9%
H
14.3
15.1
|
L
 -12.6%
H
13.5
17.3
|
L
 -24.1%
H
13.5
21.5
|
L
 9.2%
H
9.6
21.5
|
L
 376.8%
H
1.0
22
|
L
 58.4%
H
1.0
22
|
L
 44.6%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
175.4
|
4.7
|
L
H
4.7
4.7
|
L
 -0.4%
H
4.1
5.0
|
L
 -6.2%
H
4.1
5.4
|
L
 6.8%
H
4.0
5.4
|
L
 11.7%
H
3.4
5.4
|
L
 -20.5%
H
3.3
12.7
|
L
 -80.4%
H
3.3
32.0
|
L
 -84.3%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
57.3
|
0.4
|
L
H
0.3
0.4
|
L
 -7.7%
H
0.3
0.4
|
L
 -16.3%
H
0.3
0.5
|
L
 -82%
H
0.2
2.4
|
L
 -86.1%
H
0.2
3.1
|
L
 -52%
H
0.2
5.0
|
L
 -91.0%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
348.1
|
2.8
|
L
H
2.6
2.9
|
L
 20.1%
H
2.2
2.9
|
L
 -4.8%
H
2.2
3.1
|
L
 41.8%
H
1.8
3.1
|
L
 186.5%
H
0.6
3.1
|
L
 21.7%
H
0.6
4.7
|
L
 -79.4%
H
0.6
15.0
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
154.1
|
2.2
|
L
 -3.1%
H
2.1
2.2
|
L
 -5.2%
H
2.1
2.4
|
L
 -8.1%
H
2.1
2.8
|
L
 21.2%
H
1.7
2.8
|
L
 42.8%
H
1.3
2.8
|
L
 -43.5%
H
1.3
16.2
|
L
 -94.7%
H
1.3
43.2
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
19.2
|
L
 -1.6%
H
18.2
19.4
|
L
 -14.0%
H
18.2
22.3
|
L
 3.1%
H
17.3
26.4
|
L
 -6.6%
H
15.9
26.4
|
L
 6.7%
H
14.7
37.3
|
L
 48.0%
H
12.2
37.3
|
L
 -91.8%
H
7.5
268
|
L
 -88.5%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.9
|
L
 0.1%
H
7.8
8.0
|
L
 -0.1%
H
7.8
8.1
|
L
 -4.7%
H
7.7
8.4
|
L
 9.1%
H
7.1
8.8
|
L
 11.0%
H
6.2
8.8
|
L
 472.5%
H
0.0
8.8
|
L
 -78.5%
H
0.0
37.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
4.9
|
1.5
|
L
H
1.4
1.5
|
L
 -8.1%
H
1.4
1.7
|
L
 -5.1%
H
1.3
1.7
|
L
 -82.8%
H
1.3
10
|
L
 -91.5%
H
1.3
23.1
|
L
 -97.6%
H
1.3
83.6
|
L
 -100.0%
H
1.3
17344.8
|
L
H
1.3
1424940
|
| Intellia Therapeutics Inc |
|
1,553.5
|
13.2
|
L
H
12.7
13.5
|
L
 2.3%
H
12.6
13.7
|
L
 0.8%
H
12.4
15.5
|
L
 42.5%
H
8.9
17.1
|
L
 41.4%
H
5.9
28.3
|
L
 -67.0%
H
5.9
47.5
|
L
 -80.0%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,630.6
|
97.1
|
L
H
96.0
98.5
|
L
 -1.0%
H
96.0
101.8
|
L
 -6.7%
H
96.0
107.6
|
L
 -6.5%
H
95.5
113.0
|
L
 25.1%
H
55.5
113.0
|
L
 219.2%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,587.0
|
9.7
|
L
H
9.4
9.8
|
L
 -5.4%
H
9.4
10.9
|
L
 5.6%
H
9.0
12.0
|
L
 46.3%
H
6.6
12.0
|
L
 23.1%
H
5.0
12.0
|
L
 63.7%
H
3.5
23.9
|
L
 -95.7%
H
3.5
277.8
|
L
 -90.4%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
7.1
|
1.7
|
L
H
1.6
1.8
|
L
 -14.1%
H
1.6
2.1
|
L
 -20.1%
H
1.6
2.3
|
L
 -52.0%
H
1.6
3.8
|
L
 -100.0%
H
1.6
53600
|
L
 -100.0%
H
1.6
1750000
|
L
 -100.0%
H
1.6
5660000
|
L
H
1.6
32000000
|
| Insight Molecular Diagnostics Inc |
|
112.4
|
3.9
|
L
 -10.5%
H
3.9
4.4
|
L
 -19.8%
H
3.9
5.4
|
L
 -27.8%
H
3.9
6.2
|
L
 -27.5%
H
3.9
7.5
|
L
 12%
H
2.3
8.5
|
L
 -26.6%
H
1.9
8.5
|
L
 -95.9%
H
1.9
125
|
L
 -96.4%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
83.2
|
1.6
|
L
H
1.5
1.7
|
L
 -4.7%
H
1.5
1.7
|
L
 -8.0%
H
1.5
1.9
|
L
 -20.2%
H
1.5
3.2
|
L
 22.7%
H
1.0
3.4
|
L
 4.5%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
105.5
|
1.0
|
L
H
0.9
1
|
L
 2.1%
H
0.9
1.0
|
L
 -2%
H
0.9
1.2
|
L
 -3.0%
H
0.8
1.3
|
L
 58.1%
H
0.3
1.5
|
L
 -27.4%
H
0.3
3.4
|
L
 -67.9%
H
0.3
4.8
|
L
 -75.7%
H
0.3
8.5
|
| Traws Pharma Inc |
|
17.4
|
2.2
|
L
H
2
2.2
|
L
 7.9%
H
1.7
2.2
|
L
 38.9%
H
1.4
2.5
|
L
 70.3%
H
1.1
3.0
|
L
 -21.3%
H
1.0
3.3
|
L
 -89.1%
H
1.0
36.3
|
L
 -99.5%
H
1.0
457.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.6
|
1.8
|
L
H
1.7
1.8
|
L
 -4.3%
H
1.7
1.9
|
L
 -10.6%
H
1.7
2.3
|
L
 -10.1%
H
1.7
3.4
|
L
 -45.6%
H
0.3
5.3
|
L
 -92.5%
H
0.3
28.0
|
L
 -98.6%
H
0.3
135
|
L
 -99.7%
H
0.3
1197.6
|
| Passage Bio Inc |
|
23.7
|
7.4
|
L
H
6.8
7.5
|
L
 -8.9%
H
6.8
8.2
|
L
 -18.1%
H
6.8
9.8
|
L
 -23.0%
H
6.8
20
|
L
 -20.7%
H
5.1
20
|
L
 -67.1%
H
5.1
35.8
|
L
 -98.1%
H
5.1
399.7
|
L
H
5.1
764.6
|
| Vaxcyte Inc |
|
7,768.8
|
54.0
|
L
H
53.5
54.8
|
L
 -4.0%
H
53.2
57.9
|
L
 -5.8%
H
53.2
65
|
L
 16.3%
H
43.9
65
|
L
 -29.1%
H
27.7
76.6
|
L
 43.6%
H
27.7
121.1
|
L
 112.4%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
329.7
|
4.8
|
L
H
4.7
5.1
|
L
 -22.4%
H
4.7
6.3
|
L
 -28.4%
H
4.7
7.1
|
L
 -12.0%
H
4.2
7.8
|
L
 136.1%
H
0.9
7.8
|
L
 -73.1%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,174.7
|
3.3
|
L
H
3.1
3.4
|
L
 1.2%
H
3.1
3.6
|
L
 -26.4%
H
3.1
4.6
|
L
 -23.2%
H
3.1
5.5
|
L
 85.5%
H
1.1
5.5
|
L
 225.5%
H
0.7
5.5
|
L
 -59.5%
H
0.7
8.7
|
L
 -91.1%
H
0.7
39.5
|
| Phio Pharma Corp |
|
13.7
|
1.2
|
L
H
1.1
1.2
|
L
 -5.6%
H
1.1
1.3
|
L
 3.5%
H
1.0
1.3
|
L
 10.3%
H
0.8
1.9
|
L
 -12.6%
H
0.8
4.2
|
L
 -97.7%
H
0.6
110.4
|
L
 -99.6%
H
0.6
334.8
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
82.3
|
1.3
|
L
H
1.3
1.3
|
L
 -5.7%
H
1.3
1.4
|
L
 2.3%
H
1.2
1.4
|
L
 8.1%
H
1.1
1.4
|
L
 -17.9%
H
1.1
2.0
|
L
 -95.1%
H
1.1
30.9
|
L
 -96.6%
H
1.1
42.3
|
L
H
1.1
43.9
|
| Pluri Inc |
|
31.5
|
3.1
|
L
 -4.9%
H
3.1
3.2
|
L
 -3.1%
H
3.1
3.5
|
L
 -15.0%
H
3.1
3.8
|
L
 -7.9%
H
2.9
3.9
|
L
 -30.3%
H
2.8
7.1
|
L
 -54.5%
H
0.7
8.6
|
L
 -93.0%
H
0.7
45.8
|
L
 -97.4%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
201.0
|
3.2
|
L
H
3.1
3.4
|
L
 -5.3%
H
3.0
3.7
|
L
 40.5%
H
2.2
4
|
L
 49.1%
H
1.8
4
|
L
 331.1%
H
0.6
4.2
|
L
 -52.7%
H
0.6
8.6
|
L
 -94.2%
H
0.6
60.0
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
664.4
|
3.7
|
L
H
3.5
3.8
|
L
 -1.3%
H
3.5
3.8
|
L
 10.5%
H
3.2
4.8
|
L
 1.1%
H
3.2
4.8
|
L
 84%
H
1.1
6.9
|
L
 -70.1%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
276.0
|
2.0
|
L
 -6.3%
H
1.9
2.1
|
L
 -13.0%
H
1.9
2.4
|
L
 -11.0%
H
1.9
2.6
|
L
 -17.7%
H
1.7
2.6
|
L
 97.0%
H
0.5
7.1
|
L
 -84.3%
H
0.5
13.8
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
459.7
|
8.5
|
L
H
8.4
8.6
|
L
 -8.3%
H
8.4
9.5
|
L
 -5.4%
H
8.2
10.3
|
L
 -7.3%
H
8.2
10.5
|
L
 -33.7%
H
4.3
13.7
|
L
 -82.3%
H
4.3
79.7
|
L
 -64.9%
H
4.3
79.8
|
L
 -77.1%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
8.0
|
0.3
|
L
H
0.3
0.4
|
L
 -15%
H
0.3
0.4
|
L
 -26.1%
H
0.3
0.5
|
L
 -52.8%
H
0.3
3.3
|
L
 -91.9%
H
0.3
15.8
|
L
 -99.4%
H
0.3
88
|
L
 -99.9%
H
0.3
899.5
|
L
 -99.9%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
6,488.1
|
101.7
|
L
H
98.3
105.7
|
L
 6.6%
H
90.6
105.7
|
L
 22.4%
H
77
105.7
|
L
 18.2%
H
77
105.7
|
L
 87.1%
H
39.6
105.7
|
L
 353.5%
H
13.7
105.7
|
L
 226.4%
H
6.9
105.7
|
L
H
4.5
105.7
|
| PureTech Health Plc ADR |
|
392.9
|
16.3
|
L
 -0.1%
H
16
16.3
|
L
 -3.6%
H
16
16.9
|
L
 -10.1%
H
16
18.1
|
L
 -4.6%
H
16
19.9
|
L
 -8.9%
H
13.3
20
|
L
 -39.8%
H
13.3
34
|
L
 -72.9%
H
13.3
65.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
5.0
|
0.1
|
L
H
0.1
0.1
|
L
 -18.2%
H
0.1
0.1
|
L
 -43.8%
H
0.1
0.2
|
L
 -97.5%
H
0.1
3.8
|
L
 -93.4%
H
0.1
4.6
|
L
 -89.2%
H
0.1
4.6
|
L
 -99.8%
H
0.1
122.0
|
L
H
0.1
122.0
|
| uniQure NV |
|
954.2
|
15.3
|
L
H
14.2
15.8
|
L
 -9.9%
H
14.2
17.3
|
L
 -37.5%
H
8.7
25.4
|
L
 -36.4%
H
8.7
28.8
|
L
 8.7%
H
7.8
71.5
|
L
 -21.1%
H
3.7
71.5
|
L
 -54.3%
H
3.7
71.5
|
L
 28.9%
H
3.7
82.5
|
| Rain Oncology Inc |
|
111.3
|
3.1
|
L
H
2.9
3.8
|
L
 11.7%
H
2.7
3.8
|
L
 16.4%
H
2.5
3.8
|
L
 -58.2%
H
2.1
8.5
|
L
 45.7%
H
1.7
9.2
|
L
 -61.0%
H
0.8
10.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
112.2
|
1.2
|
L
H
1.1
1.2
|
L
 -10.9%
H
1.1
1.4
|
L
 -13.5%
H
1.1
1.4
|
L
 -23.8%
H
1.1
1.5
|
L
 -21.8%
H
0.4
3.9
|
L
 -81.8%
H
0.4
8.8
|
L
 -99.5%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
476.6
|
4.4
|
L
H
4.2
4.5
|
L
 -10.8%
H
4.2
5.1
|
L
 17.4%
H
3.6
5.5
|
L
 35.9%
H
3
5.5
|
L
 -48.1%
H
2.2
8.8
|
L
 -75.0%
H
2.2
32.5
|
L
 -92.0%
H
2.2
58.2
|
L
 -85.6%
H
2.2
67.5
|
| Replimune Grp Inc |
|
568.9
|
6.9
|
L
H
6.5
7.0
|
L
 -9.1%
H
6.5
7.8
|
L
 -19.4%
H
6.5
9.1
|
L
 -30.3%
H
6.5
10.3
|
L
 -40.1%
H
2.7
13.2
|
L
 -64.8%
H
2.7
24.8
|
L
 -80.5%
H
2.7
40.2
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
4.5
|
1.2
|
L
H
1.1
1.3
|
L
 -2.4%
H
1.1
1.3
|
L
 -14.3%
H
1.1
1.5
|
L
 -66.4%
H
1.1
5.8
|
L
 -96.6%
H
1.1
44.8
|
L
 -100.0%
H
1.1
9561.6
|
L
 -100.0%
H
1.1
2276064
|
L
H
1.1
2276064
|
| Relay Therapeutics Inc |
|
1,787.3
|
10
|
L
H
9.7
10.2
|
L
 -5.2%
H
9.7
11.5
|
L
 12.9%
H
8.4
11.5
|
L
 19.1%
H
7.0
11.5
|
L
 199.4%
H
1.8
11.5
|
L
 -36.6%
H
1.8
19.2
|
L
 -73.2%
H
1.8
39.7
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
8.5
|
9.3
|
L
 -2.5%
H
9.1
9.3
|
L
 -5%
H
9.1
9.8
|
L
 -10.3%
H
8.9
10.4
|
L
 17.6%
H
6.1
12.6
|
L
 -56.3%
H
6.1
46.8
|
L
 -100.0%
H
6.1
362374.6
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,780.0
|
3.4
|
L
H
3.2
3.5
|
L
 2.4%
H
3.2
3.5
|
L
 -9.4%
H
3.2
4.1
|
L
 -20.9%
H
3.0
5.2
|
L
 -48.8%
H
3.0
7.2
|
L
 -54.5%
H
3.0
16.7
|
L
H
3.0
42.8
|
L
H
3.0
42.8
|
| Rhythm Pharma Inc |
|
6,166.8
|
90.3
|
L
H
84
90.5
|
L
 -0.9%
H
82
91.3
|
L
 -12.5%
H
82
103.5
|
L
 -19.5%
H
82
115.0
|
L
 63.6%
H
45.9
122.2
|
L
 403.4%
H
15.5
122.2
|
L
 253.0%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
192.6
|
3.8
|
L
H
3.7
4.0
|
L
 -17.7%
H
3.7
4.7
|
L
 -0.3%
H
3.5
5.2
|
L
 -5.3%
H
3.4
5.2
|
L
 133.3%
H
1
6.6
|
L
 641.2%
H
0.4
6.6
|
L
 -61.8%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
846.0
|
3.2
|
L
H
3.0
3.2
|
L
 2.6%
H
3.0
3.5
|
L
 -23.4%
H
3
4.5
|
L
 -27.3%
H
3
5.2
|
L
 35.5%
H
1.3
6.6
|
L
 -9.4%
H
1.3
12
|
L
 -90.2%
H
1.3
33.8
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
88.4
|
1.8
|
L
H
1.8
1.9
|
L
 -6.2%
H
1.8
2.1
|
L
 -15.7%
H
1.8
2.5
|
L
 -16.1%
H
1.8
2.5
|
L
 -32.7%
H
1.2
5.0
|
L
 -93.1%
H
1.2
42.2
|
L
 -96.8%
H
1.2
146.2
|
L
 -87.5%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
97.6
|
1.7
|
L
 0.6%
H
1.7
1.7
|
L
 -5.5%
H
1.7
1.8
|
L
 -16.4%
H
1.7
2.2
|
L
 -3.4%
H
1.7
2.2
|
L
 -9.9%
H
1.6
2.4
|
L
 -61.5%
H
1.5
5.7
|
L
 -96.7%
H
1.5
57.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,017.4
|
6.6
|
L
 -1.2%
H
6.4
6.8
|
L
 -19.1%
H
6.4
8.7
|
L
 -3.1%
H
6.4
9.3
|
L
 -9%
H
6.1
9.3
|
L
 -36.0%
H
6.0
15.6
|
L
 -36.0%
H
6.0
15.6
|
L
 -36.0%
H
6.0
15.6
|
L
 -36.0%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
126.4
|
0.3
|
L
H
0.3
0.4
|
L
 -15%
H
0.3
0.4
|
L
 -10.5%
H
0.3
0.6
|
L
 -24.4%
H
0.3
0.6
|
L
 -60.9%
H
0.3
0.9
|
L
 -83.1%
H
0.3
3.2
|
L
 -97.4%
H
0.3
13.9
|
L
 -93.7%
H
0.3
27.5
|
| Solid Biosciences Inc |
|
554.7
|
7.1
|
L
H
6.8
7.3
|
L
 -7.7%
H
6.8
8.0
|
L
 21.1%
H
5.5
8.7
|
L
 19.9%
H
4.9
8.7
|
L
 47.7%
H
2.4
8.7
|
L
 73.2%
H
1.8
15.1
|
L
 -91.8%
H
1.8
93.8
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
12,188.9
|
15.7
|
L
H
15.3
15.8
|
L
 1.7%
H
15.3
16.7
|
L
 -1.0%
H
14.6
16.8
|
L
 -11.8%
H
13.8
20.2
|
L
 -21.8%
H
13.8
36.9
|
L
 841.3%
H
1.3
36.9
|
L
 160.3%
H
0.7
36.9
|
L
 106.8%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,116.8
|
24
|
L
H
23.3
24.2
|
L
 0.0%
H
23
24.4
|
L
 16.3%
H
19.2
25.2
|
L
 15.6%
H
19.2
25.2
|
L
 82.9%
H
8.6
25.2
|
L
 7.9%
H
8.6
25.3
|
L
 4.6%
H
8.6
29.9
|
L
 108.3%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
38.5
|
30.6
|
L
H
30.0
32.1
|
L
 -2.1%
H
28.5
33.2
|
L
 12.2%
H
26.1
36.8
|
L
 244.8%
H
8.4
36.8
|
L
 234.3%
H
5
36.8
|
L
 7.6%
H
5
38.8
|
L
 -90.1%
H
5
316.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
23.7
|
0.9
|
L
H
0.9
1.0
|
L
 -10%
H
0.9
1
|
L
 1.1%
H
0.8
1.0
|
L
 -25%
H
0.8
1.3
|
L
 -75.1%
H
0.8
5.1
|
L
 -92.6%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
81.0
|
59.0
|
L
 0.5%
H
58.1
64.3
|
L
 -1.4%
H
57
65
|
L
 12.2%
H
48.1
68.1
|
L
 -25.0%
H
48.1
91.1
|
L
 138.6%
H
4.3
240
|
L
 -66.1%
H
4.3
446.3
|
L
 -95.5%
H
4.3
1388.3
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
139.2
|
2.5
|
L
 0.4%
H
2.4
2.5
|
L
 -4.6%
H
2.4
2.7
|
L
 2.9%
H
2.1
2.7
|
L
 6.5%
H
2.1
2.7
|
L
 225%
H
0.5
3.2
|
L
 81.6%
H
0.5
3.2
|
L
 -84.4%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
5,227.2
|
45.5
|
L
H
38.8
45.6
|
L
 8.9%
H
38.8
45.6
|
L
 -4.6%
H
38.8
48.8
|
L
 3.6%
H
38.8
49.8
|
L
 33.9%
H
22.7
49.8
|
L
 384.0%
H
5.6
49.8
|
L
 -27.3%
H
4.3
65.1
|
L
H
4.3
70
|
| Surrozen Inc |
|
228.3
|
26.6
|
L
H
24.9
26.6
|
L
 2.8%
H
23.4
27.9
|
L
 -1.1%
H
23.4
29.6
|
L
 22.4%
H
16.8
29.6
|
L
 135.3%
H
5.9
29.6
|
L
 2892.1%
H
0.3
29.6
|
L
H
0.3
29.6
|
L
H
0.3
29.6
|
| Stoke Therapeutics Inc |
|
1,963.2
|
33.2
|
L
H
29.9
33.7
|
L
 -9.0%
H
29.9
37.5
|
L
 -3.4%
H
29.9
40.2
|
L
 3.9%
H
25.2
40.2
|
L
 301.8%
H
5.4
40.2
|
L
 272.1%
H
3.4
40.2
|
L
 -30.7%
H
3.4
50.3
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
436.5
|
6.1
|
L
H
5.9
6.1
|
L
 -0.5%
H
5.8
6.3
|
L
 49.9%
H
3.8
6.3
|
L
 93.7%
H
3.0
6.3
|
L
 412.6%
H
0.7
6.3
|
L
 86.0%
H
0.7
11.8
|
L
 -81.5%
H
0.7
38.9
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
2.5
|
1.9
|
L
H
1.8
2.1
|
L
 -33.7%
H
1.8
2.8
|
L
 -40.4%
H
1.8
3.6
|
L
 -36.5%
H
1.4
8.6
|
L
 -75.8%
H
1.4
17.7
|
L
H
1.4
2076
|
L
H
1.4
2076
|
L
H
1.4
2076
|
| Alaunos Therapeutics Inc |
|
7.4
|
3.3
|
L
 1.2%
H
3.1
3.4
|
L
 3.8%
H
3.0
3.5
|
L
 27.3%
H
2.5
3.7
|
L
 -7.0%
H
2.3
4.0
|
L
 129.9%
H
1.3
6.2
|
L
 604.3%
H
0.0
6.2
|
L
 -17.3%
H
0.0
6.2
|
L
 -56.8%
H
0.0
9.2
|
| Tscan Therapeutics Inc |
|
59.2
|
1.0
|
L
H
1.0
1.1
|
L
 -8.0%
H
1.0
1.2
|
L
 2.0%
H
1.0
1.3
|
L
 15.6%
H
0.9
1.3
|
L
 -38.8%
H
0.9
2.6
|
L
 -61.5%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
8,071.4
|
51.6
|
L
H
50.0
52.4
|
L
 0.2%
H
48.3
52.6
|
L
 -11.4%
H
48.3
59.1
|
L
 -11.5%
H
48.3
72.2
|
L
 -15.3%
H
46.0
72.2
|
L
 -28.7%
H
46.0
89.9
|
L
 -45.0%
H
46.0
136.0
|
L
 117.9%
H
22.9
136.0
|
| Terns Pharma Inc |
|
5,336.1
|
49.1
|
L
H
46.8
49.5
|
L
 10.9%
H
44.8
49.5
|
L
 24.4%
H
38.8
49.5
|
L
 23.0%
H
33.4
49.5
|
L
 1452.5%
H
1.9
49.5
|
L
 386.2%
H
1.9
49.5
|
L
 80.0%
H
1.5
49.5
|
L
H
1.5
49.5
|
| Instil Bio Inc |
|
57.5
|
8.5
|
L
H
8.1
8.5
|
L
 -3.1%
H
8
8.8
|
L
 -10.7%
H
8
9.5
|
L
 -24.8%
H
5.7
12.9
|
L
 -57.3%
H
5.7
42.8
|
L
 1225%
H
0.3
92
|
L
 -67.9%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
2,756.7
|
19.3
|
L
H
18.5
19.6
|
L
 12.7%
H
16.8
19.6
|
L
 56.4%
H
10.8
19.6
|
L
 126.8%
H
8.3
19.6
|
L
 1023.3%
H
1.0
19.6
|
L
 358.9%
H
1.0
19.6
|
L
H
1.0
19.6
|
L
H
1.0
19.6
|
| Entrada Therapeutics Inc |
|
458.6
|
12.0
|
L
H
11.2
12.1
|
L
 -7.7%
H
11.2
13.3
|
L
 5%
H
10.6
13.7
|
L
 9.1%
H
9.3
13.7
|
L
 11.4%
H
4.9
13.7
|
L
 -22.9%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,372.1
|
10.7
|
L
 0.1%
H
10.5
10.9
|
L
 -4.5%
H
10.5
12.0
|
L
 1.3%
H
10.4
13.6
|
L
 -17.8%
H
9.8
13.6
|
L
 57.1%
H
4.9
14.4
|
L
 497.8%
H
1.0
14.4
|
L
 289.1%
H
0.5
14.4
|
L
H
0.5
14.4
|
| Taysha Gene Therapies Inc |
|
1,249.1
|
4.6
|
L
H
4.3
4.7
|
L
 -1.1%
H
4.3
4.7
|
L
 -4.8%
H
4.3
5.1
|
L
 -16.9%
H
4.3
6.0
|
L
 149.2%
H
1.1
6.0
|
L
 551.4%
H
0.5
6.0
|
L
 -80.9%
H
0.5
27
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
2,746.8
|
44.8
|
L
H
42.7
45.7
|
L
 4.1%
H
42.7
47.4
|
L
 -14.7%
H
42.5
50.9
|
L
 37.8%
H
31
57.9
|
L
 7.4%
H
23.3
57.9
|
L
 171.4%
H
11.5
60.9
|
L
 -65.6%
H
11.5
150.3
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
2,348.1
|
18.4
|
L
H
16.9
18.4
|
L
 -3.0%
H
15.9
19.8
|
L
 -4.2%
H
15.9
23.3
|
L
 14.5%
H
15.9
23.6
|
L
 78.6%
H
6.8
23.6
|
L
 -61.8%
H
6.8
63.6
|
L
 -89.7%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
905.0
|
18.6
|
L
H
18.2
18.9
|
L
 -1.1%
H
17.9
19.2
|
L
 -14.7%
H
17.9
22.0
|
L
 -18.5%
H
17.9
24.1
|
L
 59.4%
H
3.4
30
|
L
 118.7%
H
3.4
30
|
L
 -6.9%
H
3.4
30
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
2,952.0
|
41.4
|
L
H
37.5
41.5
|
L
 0.5%
H
37.5
42.7
|
L
 -1.9%
H
37.5
45.4
|
L
 -19.2%
H
37.5
56.1
|
L
 49.4%
H
18.5
56.1
|
L
 480.2%
H
6.0
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,499.0
|
9.4
|
L
H
9.1
9.6
|
L
 -1.1%
H
9.0
9.9
|
L
 20.0%
H
7.3
10.9
|
L
 62.9%
H
5.6
10.9
|
L
 35.0%
H
4.2
10.9
|
L
 -60.4%
H
4.2
27.5
|
L
 -82.5%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
546.8
|
13.2
|
L
H
12.7
13.8
|
L
 -6.3%
H
12.7
14.5
|
L
 -1.1%
H
12.7
17.1
|
L
 6.1%
H
10.3
18.6
|
L
 1467.9%
H
0.1
50.0
|
L
 156.2%
H
0.1
50.0
|
L
 -67.6%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
511.2
|
5.8
|
L
H
5.3
6.0
|
L
 -0.3%
H
5.3
6
|
L
 -2.0%
H
5.3
6.8
|
L
 -25%
H
5.3
8.9
|
L
 -16.6%
H
4.0
11.2
|
L
 6.2%
H
2.1
15.2
|
L
 -80.1%
H
2.1
59.2
|
L
 -66.1%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
25.4
|
0.6
|
L
 4.9%
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 8.5%
H
0.5
0.7
|
L
 -18.0%
H
0.4
0.8
|
L
 -76.5%
H
0.4
5.1
|
L
 -84.5%
H
0.4
24.7
|
L
 -99.1%
H
0.4
106.5
|
L
 -99.7%
H
0.4
270
|
| Voyager Therapeutics Inc |
|
222.9
|
3.7
|
L
H
3.7
3.8
|
L
 -23.2%
H
3.7
4.9
|
L
 9.4%
H
3.3
5.5
|
L
 -6.5%
H
3.3
5.5
|
L
 -8.6%
H
2.6
5.6
|
L
 -52.8%
H
2.6
14.3
|
L
 -32.5%
H
2.5
14.3
|
L
 -61.0%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
911.3
|
10.5
|
L
 -0.1%
H
10.3
10.9
|
L
 0.1%
H
10.3
11.5
|
L
H
10
12.2
|
L
 29.8%
H
8.1
12.2
|
L
 55.9%
H
5.4
12.3
|
L
 -1.5%
H
3.6
17.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
2,281.6
|
12.1
|
L
H
11.5
12.4
|
L
 -9.2%
H
11.5
13.7
|
L
 -7.9%
H
11.5
15.5
|
L
 -24.2%
H
11.5
19.5
|
L
 20.7%
H
5.3
21.7
|
L
 203%
H
3.2
21.7
|
L
 21.9%
H
1.2
21.7
|
L
 -16.9%
H
1.2
56
|
| XBiotech Inc |
|
71.6
|
2.4
|
L
 4.4%
H
2.2
2.4
|
L
 0.4%
H
2.2
2.5
|
L
 -1.3%
H
2.2
2.5
|
L
 -6%
H
2.2
2.7
|
L
 -32.5%
H
2.1
3.6
|
L
 -31.3%
H
2.1
10.0
|
L
 -88.1%
H
2.1
20.1
|
L
 -73.6%
H
2.1
26.4
|
| Exicure Inc |
|
30.3
|
4.8
|
L
H
4.5
4.9
|
L
 20.6%
H
4.0
4.9
|
L
 33.1%
H
3.5
4.9
|
L
 -19.8%
H
3.5
6.6
|
L
 -63.2%
H
3.1
15.9
|
L
 -5.9%
H
0.3
36
|
L
 -98.7%
H
0.3
396
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
962.2
|
5.6
|
L
H
5.4
5.6
|
L
 1.8%
H
5.4
5.7
|
L
 -17.1%
H
5.4
7.1
|
L
 -24.0%
H
5.4
8.4
|
L
 1.3%
H
3.8
10.1
|
L
 313.3%
H
1.3
10.1
|
L
 25.7%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
364.6
|
4.2
|
L
H
3.9
4.2
|
L
 7.5%
H
3.5
4.4
|
L
 34.5%
H
3.0
4.8
|
L
 15.8%
H
2.8
4.8
|
L
 1290%
H
0.2
6.6
|
L
 396.4%
H
0.2
6.6
|
L
 -57.9%
H
0.2
10.5
|
L
H
0.2
172.2
|
| Xencor Inc |
|
888.9
|
12.1
|
L
H
11.3
12.3
|
L
 4.4%
H
11.3
12.5
|
L
 3.2%
H
10.6
14.5
|
L
 -22.1%
H
10.6
16.2
|
L
 -7.8%
H
6.9
18.7
|
L
 -56.8%
H
6.9
30.2
|
L
 -73.8%
H
6.9
47.4
|
L
 1.2%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.8
|
3.6
|
L
H
3.5
3.8
|
L
 -2.4%
H
3.5
4
|
L
 -42.0%
H
3.5
6.3
|
L
 -74.9%
H
3.5
14.9
|
L
 -99.5%
H
3.5
841.8
|
L
 -100.0%
H
3.5
10167316.1
|
L
 -100.0%
H
3.5
67850460
|
L
 -100.0%
H
3.5
67850460
|
| Zentalis Pharma Inc |
|
165.8
|
2.6
|
L
H
2.5
2.6
|
L
 -6.9%
H
2.5
2.9
|
L
 1.6%
H
2.1
3.1
|
L
 82.9%
H
1.3
4.0
|
L
 43.0%
H
1.0
4.0
|
L
 -86.4%
H
1.0
31.5
|
L
 -94.2%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
580.7
|
6.1
|
L
H
5.9
6.4
|
L
 -9.9%
H
5.9
7.0
|
L
 -2.6%
H
5.9
7.4
|
L
 43.3%
H
4
7.4
|
L
 331.0%
H
1.0
7.4
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,059.0
|
18.6
|
L
H
18.2
18.7
|
L
 -1.4%
H
18.2
19.4
|
L
 -7.3%
H
17.1
20.2
|
L
 3.2%
H
16.0
20.3
|
L
 -51.0%
H
16.0
44.3
|
L
 -45.0%
H
13.5
44.3
|
L
 -86.0%
H
13.5
181.9
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
4,716.1
|
68.5
|
L
H
66.0
69.6
|
L
 -6.8%
H
66.0
76.3
|
L
 -0.6%
H
66
77.6
|
L
 -12.8%
H
60.4
84.6
|
L
 69.4%
H
26.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
| Intensity Therapeutics Inc |
|
16.0
|
6.3
|
L
 -2.3%
H
6.1
6.4
|
L
 -14.7%
H
6
7.6
|
L
 -2.9%
H
5.6
8.1
|
L
 -38.2%
H
5.4
11.1
|
L
 -86.7%
H
4.6
54.5
|
L
 -93.7%
H
4.6
286
|
L
 -93.7%
H
4.6
286
|
L
 -93.7%
H
4.6
286
|
| Renovaro Biosciences Inc |
|
9.4
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 105.3%
H
0.2
0.7
|
L
 -32.8%
H
0.2
0.7
|
L
 -62.9%
H
0.2
1.1
|
L
 -94.9%
H
0.2
7.4
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
L
H
0.2
52.5
|
| Elutia Inc (Class A) |
|
44.9
|
1.1
|
L
H
1.0
1.1
|
L
 -8.7%
H
1.0
1.2
|
L
 -6.3%
H
1.0
1.4
|
L
 78.0%
H
0.5
1.4
|
L
 -68.0%
H
0.5
3.4
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
133.6
|
3.4
|
L
H
3.2
3.5
|
L
 -19.5%
H
3.2
4.4
|
L
 -25.1%
H
3.2
5.3
|
L
 45.7%
H
2.4
5.8
|
L
 128.4%
H
1.0
9.1
|
L
 -99.0%
H
0.3
498.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
620.9
|
6.8
|
L
H
6.8
7.0
|
L
 -12.8%
H
6.8
8.0
|
L
 -19.2%
H
6.8
9.1
|
L
 -4.6%
H
6.8
9.1
|
L
 -33.9%
H
6.1
11.8
|
L
 -9.3%
H
5.6
130.5
|
L
 -9.3%
H
5.6
130.5
|
L
 -9.3%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
422.6
|
5.8
|
L
 0.5%
H
5.5
5.9
|
L
 -12.7%
H
5.5
7.0
|
L
 -7.7%
H
5.5
8
|
L
 -44.1%
H
5.5
11.0
|
L
 90.5%
H
1.5
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
109.7
|
11.1
|
L
H
10.9
11.4
|
L
 -3.8%
H
10.9
14.8
|
L
 -5.5%
H
10.6
14.8
|
L
 40.4%
H
7.7
14.9
|
L
 -53.4%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
170.8
|
6.6
|
L
H
6.4
6.8
|
L
 -19.1%
H
6.4
8.7
|
L
 -3.1%
H
6.4
9.3
|
L
 -9%
H
6.1
9.3
|
L
 -57.5%
H
6.0
16.8
|
L
 -99.5%
H
6.0
1386
|
L
 -99.8%
H
6.0
4752
|
L
H
6.0
25199.6
|
| Elevai Labs Inc |
|
2.1
|
3.8
|
L
H
3.7
4.2
|
L
 -13.9%
H
3.7
5.2
|
L
 -56.4%
H
3.7
8.3
|
L
 -93.0%
H
3.7
57.5
|
L
 -99.2%
H
3.7
686.3
|
L
H
3.7
499117.9
|
L
H
3.7
499117.9
|
L
H
3.7
499117.9
|
| Spyre Therapeutics Inc |
|
3,323.0
|
42.3
|
L
H
41.7
43.2
|
L
 4.7%
H
39
45.4
|
L
 11.9%
H
37.8
45.8
|
L
 26.7%
H
28
45.8
|
L
 130.0%
H
10.9
45.8
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
| Neurogene Inc |
|
297.2
|
19.2
|
L
H
18.2
19.4
|
L
 -14.0%
H
18.2
22.3
|
L
 3.1%
H
17.3
26.4
|
L
 -6.6%
H
15.9
26.4
|
L
 24.5%
H
6.9
37.3
|
L
 35.3%
H
6.9
74.5
|
L
 35.3%
H
6.9
74.5
|
L
 35.3%
H
6.9
74.5
|
| Cg Oncology Inc |
|
5,560.9
|
65.9
|
L
H
63.3
66.0
|
L
 4.6%
H
62.1
69.4
|
L
 16.7%
H
55
69.4
|
L
 68.7%
H
39.0
69.4
|
L
 135.0%
H
14.8
69.4
|
L
H
14.8
69.4
|
L
H
14.8
69.4
|
L
H
14.8
69.4
|
| FibroBiologics Inc |
|
17.7
|
0.3
|
L
H
0.2
0.3
|
L
 -23.5%
H
0.2
0.4
|
L
 4%
H
0.2
0.5
|
L
H
0.2
0.5
|
L
 -74.5%
H
0.2
1.5
|
L
H
0.2
55
|
L
H
0.2
55
|
L
H
0.2
55
|
| Kyverna Therapeutics Inc |
|
509.0
|
8.5
|
L
H
8.3
8.7
|
L
 -2.6%
H
8.3
9.3
|
L
 5.4%
H
7.7
9.7
|
L
 18.8%
H
7.2
10.6
|
L
 260.3%
H
1.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
55.3
|
1.5
|
L
 2.1%
H
1.4
1.5
|
L
 -6.4%
H
1.4
1.6
|
L
 -3.3%
H
1.4
1.8
|
L
 -16.5%
H
1.4
1.9
|
L
 -14.0%
H
1.2
4.0
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
21.5
|
5.3
|
L
H
5.0
5.3
|
L
 -16.8%
H
4.9
7.5
|
L
 -64.5%
H
4.9
15
|
L
 -72.1%
H
4.9
20.9
|
L
 -90.7%
H
4.9
75.5
|
L
H
4.9
1054.5
|
L
H
4.9
1054.5
|
L
H
4.9
1054.5
|
| NeOnc Tech Holdings Inc |
|
195.0
|
8
|
L
 -1.4%
H
8
8.4
|
L
 -11.1%
H
8.0
9.7
|
L
 -7.0%
H
8.0
10.4
|
L
 14.1%
H
7.0
11.4
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
359.5
|
11.5
|
L
H
11.2
11.9
|
L
 -2.8%
H
11.2
12.7
|
L
 -4.7%
H
11.2
15.0
|
L
 -36.2%
H
11.2
21.8
|
L
 -55.0%
H
11.2
50.4
|
L
 -53.9%
H
11.2
50.4
|
L
 -53.9%
H
11.2
50.4
|
L
 -53.9%
H
11.2
50.4
|
| Boundless Bio Inc |
|
25.8
|
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 -5.7%
H
1.0
1.4
|
L
 -26.8%
H
1.0
1.8
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
452.1
|
12.1
|
L
H
11.8
13.0
|
L
 -12.6%
H
11.8
14.4
|
L
 -24.3%
H
11.8
16.3
|
L
 3.2%
H
8.6
16.3
|
L
 61.7%
H
3.4
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
442.7
|
7.6
|
L
 1.2%
H
7.3
7.7
|
L
 1.3%
H
7.2
8.0
|
L
 -6.4%
H
7.2
8.8
|
L
 15.9%
H
6.4
9.3
|
L
 89.1%
H
2.7
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
7.0
|
2.1
|
L
H
2.1
2.2
|
L
 -5%
H
2.1
2.6
|
L
 -23.2%
H
2.0
2.8
|
L
 -10.3%
H
2.0
5.3
|
L
 32.3%
H
1.0
5.8
|
L
 -74.9%
H
0.6
9.5
|
L
 -74.9%
H
0.6
9.5
|
L
 -74.9%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
136.4
|
5.5
|
L
H
5.4
5.9
|
L
 -18.2%
H
5.4
6.8
|
L
 21.9%
H
4.4
7.8
|
L
 16.5%
H
3.6
7.8
|
L
 24.3%
H
1.5
7.8
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,350.7
|
28.4
|
L
H
27.3
28.9
|
L
 1.7%
H
26.4
31.2
|
L
 -23.7%
H
26.4
38.2
|
L
 -6.5%
H
26.4
44.9
|
L
 238.5%
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
L
H
4.8
44.9
|
| BioAge Labs Inc |
|
878.5
|
21.0
|
L
H
19.3
21.1
|
L
 5.8%
H
18.4
22
|
L
 4.5%
H
18.4
23
|
L
 57.1%
H
11.9
24
|
L
 373.9%
H
2.9
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
59.9
|
4.4
|
L
H
3.8
4.5
|
L
 24.4%
H
3.6
4.5
|
L
 65.9%
H
2.4
4.5
|
L
 45.5%
H
2.2
4.5
|
L
 -12.4%
H
1.7
5.1
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
5.2
|
L
H
5.1
5.9
|
L
 -4.1%
H
5.0
5.9
|
L
 16.0%
H
3.9
7.8
|
L
 -19.1%
H
3.3
7.8
|
L
 124.4%
H
1.3
7.8
|
L
 124.3%
H
1.3
7.8
|
L
 124.3%
H
1.3
7.8
|
L
 124.3%
H
1.3
7.8
|
| Upstream Bio Inc |
|
452.8
|
8.4
|
L
H
8.2
8.6
|
L
 -11.2%
H
8.2
9.9
|
L
 -1.9%
H
7.3
9.9
|
L
 -71.5%
H
7.3
33.7
|
L
 -2.0%
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
12.4
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.6
|
L
 -54.6%
H
0.4
1.7
|
L
 -70.4%
H
0.4
1.7
|
L
 -92.6%
H
0.4
8.9
|
L
 -92.6%
H
0.4
8.9
|
L
 -92.6%
H
0.4
8.9
|
L
 -92.6%
H
0.4
8.9
|
| Telix Pharma Ltd (ADR) |
|
2,903.3
|
8.6
|
L
 1.9%
H
8.4
8.6
|
L
 8.6%
H
7.8
8.7
|
L
 27.7%
H
6.4
8.7
|
L
 9.9%
H
6.3
8.7
|
L
 -51.3%
H
6.3
19.9
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,620.9
|
113.9
|
L
H
109.9
116.3
|
L
 -16.6%
H
109.9
138.8
|
L
 38.4%
H
78.2
151.2
|
L
 14.2%
H
72.2
151.2
|
L
 312.6%
H
18.2
151.2
|
L
 737.6%
H
11.2
151.2
|
L
 737.6%
H
11.2
151.2
|
L
 737.6%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
1,597.0
|
35.5
|
L
H
33.2
36.2
|
L
 -3.2%
H
33.2
39.0
|
L
 -5.0%
H
32.6
39.3
|
L
 -16.2%
H
32.5
45
|
L
 155.7%
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
| Zenas Biopharma Inc |
|
1,254.5
|
23.4
|
L
H
22.0
23.8
|
L
 -4.6%
H
21.5
26.0
|
L
 -13.5%
H
21.5
27.8
|
L
 -35.4%
H
13.5
44.6
|
L
 123.2%
H
8.9
44.6
|
L
 123.2%
H
8.9
44.6
|
L
 123.2%
H
8.9
44.6
|
L
 123.2%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
1.9
|
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -40%
H
0.1
0.2
|
L
 -83.1%
H
0.1
0.7
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
L
 -95.8%
H
0.1
9.4
|
| SpyGlass Pharma Inc |
|
856.6
|
25.7
|
L
H
25.4
27.2
|
L
 -2.7%
H
25.4
28.2
|
L
 -13.4%
H
25.3
29.8
|
L
 -2.6%
H
24.7
30.6
|
L
 -2.6%
H
24.7
30.6
|
L
 -2.6%
H
24.7
30.6
|
L
 -2.6%
H
24.7
30.6
|
L
 -2.6%
H
24.7
30.6
|
| AgomAb Therapeutics NV ADR |
|
625.1
|
12.7
|
L
H
12.6
14.6
|
L
 -8.7%
H
12.6
14.6
|
L
 -18.6%
H
12.6
17.5
|
L
 -13.3%
H
12.6
17.5
|
L
 -13.3%
H
12.6
17.5
|
L
 -13.3%
H
12.6
17.5
|
L
 -13.3%
H
12.6
17.5
|
L
 -13.3%
H
12.6
17.5
|
| Generate Biomedicines Inc |
|
1,566.4
|
12.3
|
L
 4.1%
H
11.8
12.4
|
L
 -7.5%
H
11.5
13.7
|
L
 -2.9%
H
11
14.0
|
L
 -2.9%
H
11
14.0
|
L
 -2.9%
H
11
14.0
|
L
 -2.8%
H
11
14.0
|
L
 -2.8%
H
11
14.0
|
L
 -2.8%
H
11
14.0
|